Patent Application
20240246908
The present invention relates to therapeutically active compounds useful in the inhibition of transcriptional enhancer associate domain (TEAD), and to pharmaceutical compositions containing such compounds. The compounds are useful in the treatment of diseases or disorders associated with increased TEAD activity or TEAD expression, such as various cancers and chronic pain.
TEA domain transcription factors (TEAD1-4) is a family of DNA binding transcription factors which regulate the expression of genes involved in cell proliferation, cell fate, cell differentiation, organ overgrowth and organ regeneration. YAP and TAZ are TEAD transcriptional co-activators which can shuttle between the cytoplasm and the nucleus. Altered actin dynamics and the Hippo signalling pathway promote YAP and TAZ phosphorylation, cytoplasmic retention and proteasomal degradation, consequently leading to low YAP and TAZ nuclear levels and TEAD transcriptional activity.
The evolutionarily conserved Hippo signalling pathway is consisting of the large tumor suppressor 1/2 (LATS1/2), the serine/threonine kinases, sterile 20-like kinase 1/2 (MST1/2), and the adaptor proteins Salvador homolog 1 (SAV1) and MOB kinase activator 1A/B (MOB1A/B). The tumor suppressor neurofibromin 2 (NF2) (also known as Merlin) participates upstream of these kinases to inhibit YAP and TAZ activity by promoting the activation of the pathway. The Hippo pathway has been linked to many aspects of tumorigenesis, including cell proliferation, cell differentiation, cancer metastasis and cancer therapy resistance. Therefore, dysregulation in Hippo pathway signalling has been shown to drive oncogenesis across various cancer types. It has also been reported that YAP and TAZ are core mechanisms underlying the pathogenesis of chronic pain, such as chronic neuropathic pain and chronic musculoskeletal pain.
Compounds with TEAD inhibition activity have been disclosed, for example, in WO 2020/081572, WO 2020/070181 and WO 2020051099. Anti-tumor effects of a TEAD inhibitor, K-975, in vivo on malignant pleural mesothelioma has been reported in Am J Cancer Res, 2020; 10(12): 4399-4415.
There is a need for compounds targeting diseases associated with dysregulation in the Hippo pathway components, for example compounds targeting the YAP-TEAD interaction. Such compounds would be useful for the treatment of diseases or conditions wherein inhibition of TEAD is desired, such as chronic pain including neuropathic pain and various cancers including cancers which are resistant to other treatments, such as chemotherapy, immunotherapy and targeted therapies.
It has been found that compounds of formula (I) are potent inhibitors of YAP-TEAD interaction. The compounds are therefore useful for the treatment of conditions and diseases where inhibition of TEAD is desired. Such conditions and diseases include, but are not limited to, chronic pain, particularly chronic neuropathic pain and chronic musculoskeletal pain, and cancers, particularly cancers associated with dysregulation in the Hippo pathway components including YAP-TEAD. Particular cancers include, but are not restricted to, mesothelioma, squamous cell carcinomas, gynaecological cancers, bladder cancer, gastric cancer, liver cancer, lung cancer and colon cancer.
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof
According to one embodiment, the invention provides a method for the treatment of a disease or condition wherein inhibition of TEAD is desired comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof
According to one embodiment, the disease or condition wherein inhibition of TEAD is desired is cancer, for example mesothelioma, squamous cell carcinoma, a gynaecological cancer, bladder cancer, gastric cancer, liver cancer, lung cancer and colon cancer.
According to one embodiment, the disease or condition wherein inhibition of TEAD is desired is chronic pain, for example chronic neuropathic pain and chronic musculoskeletal pain.
According to one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) together with a pharmaceutically acceptable carrier.
The present application provides novel compounds of formula (I) or pharmaceutically acceptable salts thereof which are useful as TEAD inhibitors.
One of the embodiments of the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof
It is to be understood that the left bond of variants of linker L is attached to the ring A of formula (I) and the right bond to the phenyl group. The wavy line in variants of group B denotes the site of attachment to carboxamide group.
According to one embodiment, specifically provided is a compound according to formula (I) wherein A is phenyl, pyridyl or cyclohexyl. In a subgroup of the preceding embodiment, A is phenyl or cyclohexyl. In still another subgroup A is phenyl or pyridyl. In still another subgroup A is phenyl. In still another subgroup A is cyclohexyl. In still another subgroup A is pyridyl.
According to yet one embodiment, specifically provided are compounds according to any of the above embodiments wherein R42 is hydrogen.
According to one embodiment, specifically provided are compounds according to formula (Ia) or a pharmaceutically acceptable salt thereof
According to yet one embodiment, specifically provided are compounds according to any of the above embodiments wherein B is ring (1a), (3), (4), (6), (8), (9), (10), (11), (12), (13), (16), (17) or (18). In a subgroup of the preceding embodiment, B is ring (1a), (4), (10), (11), (12), (13), (16) or (17). In still another subgroup B is ring (1a), (10), (11) or (12). In still another subgroup B is ring (1a) or (12). In still another subgroup B is ring (1a). In still another subgroup B is ring (12).
In a subgroup of compounds wherein B is ring (1a) are compounds wherein R7 and R8 are hydrogen. In still another subgroup of the preceding embodiment are compounds wherein R6 is hydrogen, C1-7 alkyl or C3-7 cycloalkyl. According to another subgroup are compounds wherein R6 is —C(O)—RX, wherein RX is C1-7 alkyl or an optionally substituted 4-6 membered ring having 1-3 heteroatoms as ring atoms independently selected from O, S and N. Particular examples of such rings are pyrrolidine and azetidine rings optionally substituted by 1-2 substituents independently selected from C1-7 alkyl and oxo.
In a subgroup of compounds wherein B is ring (12) are compounds wherein R20 is hydrogen and R18 is C1-7 alkyl or C3-7 cycloalkyl. In still another subgroup of the preceding embodiment are compounds wherein R21 is hydrogen or C1-7 alkyl.
According to yet one embodiment, specifically provided are compounds according to any of the above embodiments wherein L is —O—, —S—, —NH—, —C1-7 alkyl-, —C2-7 alkenyl-, —C1-7 alkyl-O—, or —O—C1-7 alkyl-. In a subgroup of the preceding embodiment are compounds wherein L is —O—, —C2-7 alkenyl-, —C1-7 alkyl-O—, or —O—C1-7 alkyl-. In a subgroup of the preceding embodiment are compounds wherein L is —O—, —C2-7 alkenyl- or —O—C1-7 alkyl-. In still another subgroup L is —O— or —C2-7 alkenyl-. In still another subgroup L is —O—. A particular example of L being C1-7 alkyl is —CH2— group. A particular example of L being —C2-7 alkenyl- is —CH═CH— group. A particular example of L being —C1-7 alkyl-O— is —CH2—O— group. A particular example of L being —O—C1-7 alkyl- is —O—CH2— group.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein R1 is hydrogen, C1-7 alkoxy or halogen. In a subgroup of the preceding embodiment are compounds wherein R1 is C1-7 alkoxy or halogen. In a subgroup of the preceding embodiment are compounds wherein R1 is C1-7 alkoxy, particularly a methoxy group. According to one embodiment, R1 is an optionally substituted 5-6 membered heterocyclic ring having 1-3 heteroatoms as ring atoms independently selected from O, S and N. Particular examples of such rings include oxadiazolyl and pyrazolyl rings optionally substituted by 1-2 C1-7 alkyl or oxo substituents.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein R2 is hydrogen, C1-7 alkoxy or halogen. In a subgroup of the preceding embodiment are compounds wherein R2 is hydrogen or halogen. In a subgroup of the preceding embodiment are compounds wherein R2 is hydrogen.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein R3 is hydrogen, halogen or C1-7 alkoxy. In a subgroup are compounds wherein R3 is hydrogen or C1-7 alkoxy. In a subgroup are compounds wherein R3 is hydrogen.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein R1 and R3 together with the carbon atoms to which they are attached form an optionally substituted 5-6 membered ring having 0-3 heteroatoms as ring atoms independently selected from O, S and N. In a subgroup are compounds wherein R1 and R3 together with the carbon atoms to which they are attached form a 5-6 membered ring having 1-2 heteroatoms as ring atoms independently selected from O and N. In a subgroup are compounds wherein R1 and R3 together with the carbon atoms to which they are attached form a 5-6 membered ring having 1-2 heteroatoms wherein the heteroatom is O. Particular examples of such rings are furanyl, dihydrofuranyl, tetrahydrofuranyl, dioxanyl, dioxolanyl, oxazinyl, pyridinyl, 2,3-dihydro-1,4-dioxinyl, 2,3-dihydro-1,4-oxazinyl rings optionally substituted by 1-2 substituents independently selected from C1-7 alkyl and oxo.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein R1 and R3 together with the phenyl ring to which they are attached form an optionally substituted fused ring represented by any of the following groups:
wherein the left wavy line denotes the site of attachment to the L group and the right wavy line denotes the site of attachment to the carboxamide group. The optional substitution may be 1-2 substituents independently selected from C1-7 alkyl, halogen, halogen C1-7 alkyl, C1-7 alkoxy and oxo, in particular C1-7 alkyl or oxo.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein R4 is hydrogen, halogen, C1-7 alkyl, C1-7 alkoxy, halogen C1-7 alkyl or halogen C1-7 alkoxy, and R5 is hydrogen, C1-7 alkyl, C1-7 alkoxy, cyano, amino or halogen. In a subgroup are compounds wherein R4 is halogen, C1-7 alkyl, halogen C1-7 alkyl or halogen C1-7 alkoxy and R5 is hydrogen, C1-7 alkyl, cyano or halogen. In a subgroup are compounds wherein R4 is halogen C1-7 alkyl or halogen C1-7 alkoxy and R5 is hydrogen or halogen. In a subgroup are compounds wherein R4 is halogen C1-7 alkyl or halogen C1-7 alkoxy and R5 is hydrogen. In another subgroup are compounds wherein both R4 and R5 are C1-7 alkyl, for example methyl. In another subgroup are compounds wherein both R4 and R5 are halogen, for example fluoro. Particular examples of R4 being halogen C1-7 alkyl is —CF3 and —CHF2 groups. A particular example of R4 being halogen C1-7 alkoxy is —OCF3 group.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein ring A together with R4 and R5 represent any of the following groups:
wherein X is halogen and the wavy line denotes the site of attachment to the L group.
According to one embodiment, specifically provided is a compound according to any of the above embodiments wherein A together with R4 and R5 is group (1′), (2′), (3′), (4′), (7′), (8′), (10′), (11′) or (13′). In a subgroup are provided a compound according to any of the above embodiments wherein A together with R4 and R5 is group (1′), (4′), (7′), (8′), (10′) or (11′).
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein ring A together with R4 and R5 are represented by following groups:
wherein the wavy line denotes the site of attachment to the L group.
According to one embodiment, specifically provided is a compound according to any of the above embodiments wherein A together with R4 and R5 is group (1″), (2″), (3″), (4″), (7″), (11″), (12″), (13″), (15″), (17″), (19″) or (21″). In a subgroup are provided a compound according to any of the above embodiments wherein A together with R4 and R5 is group (1′″), (2″), (4″), (7″), (11″), (12″), (15″) or (21″).
According to one embodiment, specifically provided is a compound according to any of the above embodiments wherein A is phenyl or pyridyl, L is —O—, R1 is C1-7 alkoxy, R2, R3, R5, R33 and R42 are hydrogen, Z is ring (1a) or (12) and R4 is halogen C1-7 alkyl.
According to one embodiment, specifically provided are compounds according to any of the above embodiments wherein Z can also be —CH(NHR25)—(CH2)2—COOH.
According to one embodiment, specifically provided are compounds according to formula (Ib) or a pharmaceutically acceptable salt thereof
According to one embodiment, specifically provided are compounds according to formula (Ic) or a pharmaceutically acceptable salt thereof
According to still one embodiment, the present invention provides a method for the treatment of a disease or condition wherein inhibition of TEAD is desired, such as cancer and chronic pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) as defined in any of the above embodiments.
The compounds of the invention can be prepared by a variety of synthetic routes analogously to the methods known in the literature using suitable starting materials. The compounds according to formula (I) can be prepared e.g. analogously or according to the following reaction Schemes. Some compounds included in the formula (I) can be obtained by converting the functional groups of the other compounds of formula (I) obtained in accordance with the following Schemes, by well known reaction steps such as oxidation, reduction, hydrolysis, acylation, alkylation, amidation, amination, sulfonation and others. It should be noted that any appropriate leaving groups, e.g. N-protecting groups, such as a t-butoxycarbonyl (t-BOC) group or a phenylsulfonyl group, can be used in well known manner during the syntheses in order to improve the selectivity of the reaction steps.
Compounds of formula (I) can be prepared, for example, according to Scheme 1, wherein A, L, Z, R1, R2, R3, R4, R5, R33 and R42 are as defined above. In the method of Scheme 1, the aniline compound of formula [1] is coupled with a carboxylic acid derivative of formula [2] in a suitable solvent, such as anhydrous acetonitrile or DMF, in the presence of a suitable coupling reagent such as a combination of N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate and 1-methyl-1H-imidazole, or hexafluorophosphate azabenzotriazole tetramethyl uranium (HATU) and N,N-diisopropylethylamine (DIPEA) to produce a compound of formula (I).
Alternatively, compounds of formula (I), wherein R42 is H, can be prepared according to Scheme 2, wherein A, L, Z, R1, R2, R3, R4, R5 and R33 are as defined above and X is a halogen, for example bromo. In the method of Scheme 2, the compound of formula [3] is coupled with a carboxamide compound of formula [4] in a suitable solvent, such as toluene, in the presence a base, such as cesium carbonate, and a suitable catalyst system such as a combination Pd2(dba) and 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos), or copper iodide and N1,N2-dimethylcyclohexane-1,2-diamine, to produce a compound of formula (I).
Compounds of formula (I) wherein L is —O— can also be prepared, for example, according to Scheme 3, wherein A, Z, R1, R2, R3, R4 and R5 are as defined above. In the method of Scheme 3, the compound of formula [3] is condensed with a compound of formula [4] in a suitable solvent, such as tetrahydrofuran, in the presence of Mitsunobu reagents, such as triphenylphosphine (TPP) and diethyl azodicarboxylate (DEAD), to produce a compound of formula (I).
Intermediate compounds can be prepared according to the methods disclosed in the literature or as disclosed in the present disclosure.
For example, intermediate compounds of formula [1a], wherein L is —O—, can be prepared according to Scheme 4, wherein A, R1, R2, R3, R4, R5 and R33 are as defined above. In the method of Scheme 4, a compound of formula [7] is coupled with a compound of formula [8] in a suitable solvent such as dichloromethane, in the presence of a base such as pyridine and a catalyst such as diacetoxycopper to produce a compound of formula [8], which can be subsequently reduced, for example, by hydrogenation in the presence of suitable catalyst such as palladium-in-carbon to obtain the intermediate of formula [1a].
Intermediate compounds of formula [3a] wherein L is —O—, can be prepared, for example, according to Scheme 5, wherein A, R1, R2, R3, R4, R5 and R33 are as defined above and X is a halogen, for example bromo. In the method of Scheme 5, a compound of formula [9] is coupled with a compound of formula [10] in a suitable solvent such as dichloromethane, in the presence of a base such as pyridine and a catalyst such as diacetoxycopper to produce a compound of formula [3a],
Intermediate compounds of formula [5] can be prepared, for example, according to Scheme 6, wherein Z, R1, R2 and R3 are as defined above. In the method of Scheme 6, a compound of formula [11] is coupled with a compound of formula [12] in a suitable solvent such as DMF in the presence of a base such as N,N-diisopropylethylamine (DIPEA) and a coupling agent such as hexafluorophosphate azabenzotriazole tetramethyl uranium (HATU) to produce the intermediate of formula {5].
Alternatively, the compounds of formula (I) can be prepared as disclosed in the specific Examples of the present disclosure.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.
The term “subject”, as employed herein, refers to humans and animals.
The term “halo” or “halogen”, as employed herein as such or as part of another group, refers to chlorine, bromine, fluorine or iodine. Preferred halogens are chlorine and fluorine.
The term “C1-7 alkyl”, as employed herein as such or as part of another group, refers to a straight or branched chain saturated hydrocarbon group having 1, 2, 3, 4, 5, 6 or 7 carbon atom(s). Representative examples of C1-7 alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl and n-hexyl. One preferred embodiment of “C1-7 alkyl” is C1-3 alkyl. The term “C1-3 alkyl” refers to an embodiment of “C1-7 alkyl” having 1, 2 or 3 carbon atoms. Examples of “C1-3 alkyl” include, but are not limited to, methyl, ethyl, n-propyl and iso-propyl. One preferred “C1-7 alkyl” is methyl group.
The term “C2-7 alkenyl”, as employed herein as such or as part of another group, refers to an aliphatic hydrocarbon group having 2, 3, 4, 5, 6 or 7 carbon atoms and containing one or several double bonds. Representative examples include, but are not limited to, ethenyl, propenyl and hexenyl. One preferred embodiment of “C2-7 alkenyl” is C2-4 alkenyl. The term “C2-4 alkenyl” refers to a embodiment of “C2-7 alkenyl” having 2, 3 or 4 carbon atoms. Representative examples include, but are not limited to, ethenyl, propenyl and butenyl. One preferred “C2-7 alkenyl” is —CH═CH— group.
The term “C3-7 cycloalkyl”, as employed herein as such or as part of another group, refers to a saturated cyclic hydrocarbon group containing 3, 4, 5, 6 or 7 carbon atoms. Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. One preferred “C3-7 cycloalkyl” is cyclopropyl group.
The term “hydroxy”, as employed herein as such or as part of another group, refers to an —OH group.
The term “cyano”, as employed herein as such or as part of another group, refers to a —CN group.
The term “carboxy”, as employed herein as such or as part of another group, refers to —COOH group.
The term “carbonyl”, as employed herein as such or as part of another group, refers to a carbon atom double-bonded to an oxygen atom (C═O).
The term “oxo”, as employed herein as such or as part of another group, refers to oxygen atom linked to another atom by a double bond (═O).
The term “C1-7 alkoxy”, as employed herein as such or as part of another group, refers to C1-7 alkyl, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of C1-7 alkoxy include, but are not limited to methoxy, ethoxy, propoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy. One preferred embodiment of “C1-7 alkoxy” is C1-3 alkoxy. The term “C1-3 alkoxy” refers to an embodiment of “C1-7 alkoxy” having 1, 2 or 3 carbon atoms. Representative examples of C1-3 alkoxy include, but are not limited to methoxy, ethoxy, propoxy. One preferred “C1-7 alkoxy” group is methoxy.
The term “hydroxy C1-7 alkyl”, as employed herein, refers to at least one hydroxy group, as defined herein, appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. Representative examples of hydroxy C1-7 alkyl include, but are not limited to, hydroxymethyl, 2,2-dihydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 1-hydroxypropyl, 1-methyl-1-hydroxyethyl and 1-methyl-1-hydroxypropyl.
The term “halogen C1-7 alkyl”, as employed herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein. Representative examples of halogen C1-7 alkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2-chloroethyl and 3-bromo-propyl. Preferred “halogen C1-7 alkyl” groups are trifluoromethyl and difluoromethyl.
The term “halogen C1-7 alkoxy”, as employed herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through a C1-7 alkoxy group, as defined herein.
The term “C1-7 alkoxy C1-7 alkyl”, as employed herein as such or as part of another group, refers to at least one C1-7 alkoxy group, as defined herein, appended to the parent molecular moiety through a C1-7 alkyl group, as defined herein.
The term “4-10 membered carbocyclic ring”, as employed herein, refers to a saturated, partially saturated or aromatic ring with 4 to 10 ring atoms consisting of carbon atoms only. One embodiment of a “4-10 membered carbocyclic ring” is a “5-6 membered carbocyclic ring” which refers to a saturated, partially saturated or aromatic ring with 5 to 6 ring atoms consisting of carbon atoms only. Representative examples of a 4-10 membered carbocyclic ring include, but are not limited to, phenyl, cyclohexyl, cyclohexenyl, cyclopentyl, cyclopentenyl and cyclobutyl rings.
The term “substituted” as used herein in connection with various residues refers to, if not otherwise defined, to halogen substituents, such as fluorine, chlorine, bromine, iodine, or C1-7 alkyl, C3-7 cycloalkyl, hydroxy, amino, nitro, cyano, thiol C1-7 alkyl, methylsulfonyl, C1-7 alkoxy, halo C1-7 alkyl, hydroxy C1-7 alkyl or amino C1-7 alkyl substituents. Preferred are halogen, C1-7 alkyl, hydroxy, amino, halo C1-7 alkyl, C1-7 alkoxy and methylsulfonyl substituents. In one group of preferred substituents are 1-2 substituents selected from C1-7 alkyl or halogen substituents, particularly C1-3 alkyl or halogen substituents, particularly methyl, ethyl, chloro, fluoro or bromo substituents.
The “substituted” groups may contain 1 to 3, preferably 1 or 2, of the above mentioned substituents, if not otherwise defined.
Optically active enantiomers or diastereomers of compounds of formula (I) can be prepared e.g. by resolution of the racemic end product by known methods or by using suitable optically active starting materials. Similarly, racemic compounds of formula (I) can be prepared by using racemic starting materials. Resolution of racemic compounds of formula (I) or a racemic starting material thereof can be carried out, for example, by converting the racemic compound into its diastereromeric salt mixture by reaction with an optically active acid and subsequent separation of the diastereomers by crystallization. Representative examples of said optically active acids include, but are not limited to, D-tartaric acid and dibenzoyl-D-tartaric acid. Alternatively, preparative chiral chromatography may be used for resolution of the racemic mixture.
Pharmaceutically acceptable salts are well known in the field of pharmaceuticals. Non-limiting examples of suitable salts include metal salts, ammonium salts, salts with an organic base, salts with an inorganic acid, salts with organic acid, and salts with basic or acidic amino acid. Non-limiting examples of metal salts include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt, and magnesium salt. Non-limiting examples of salts with inorganic or organic acids include chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, methane sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates, ascorbates, acetates, oxalates, fumarates, hemifumarates, and succinates. Pharmaceutically acceptable esters, when applicable, may be prepared by known methods using pharmaceutically acceptable acids that are conventional in the field of pharmaceuticals and that retain the pharmacological properties of the free form. Non-limiting examples of these esters include esters of aliphatic or aromatic alcohols, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl esters. Phosphate esters and carbonate esters, are also within the scope of the invention.
The definition of formula (I) above is inclusive of all the possible isotopes and isomers, such as stereoisomers, of the compounds, including geometric isomers, for example Z and E isomers (cis and trans isomers), and optical isomers, e.g. diastereomers and enantiomers, and prodrug esters, e.g. phosphate esters and carbonate esters.
It will be appreciated by those skilled in the art that the present compounds may contain at least one chiral center. Accordingly, the compounds may exist in optically active or racemic forms. It is to be understood that the formula (I) includes any racemic or optically active form, or mixtures thereof. In one embodiment, the compounds are the pure (R)-isomers. In another embodiment, the compounds are the pure (S)-isomers. In another embodiment, the compounds are a mixture of the (R) and the (S) isomers. In another embodiment, the compounds are a racemic mixture comprising an equal amount of the (R) and the (S) isomers. The compounds may contain two chiral centers. In such case, according to one embodiment, the compounds are a mixture of diasteromers. According to another embodiment, the compounds of the invention are a mixture of enantiomers. According to still another embodiment, the compounds are pure enantiomers. The individual isomers may be obtained using the corresponding isomeric forms of the starting material or they may be separated after the preparation of the end compound according to conventional separation methods. For the separation of optical isomers, e.g. enantiomers or diastereomers, from the mixture thereof the conventional resolution methods, e.g. fractional crystallisation, may be used.
The present compounds may also exist as tautomers or equilibrium mixtures thereof wherein a proton of a compound shifts from one atom to another. Examples of tautomerism include, but are not limited to, amido-imido, keto-enol, phenol-keto, oxime-nitroso, nitro-aci, imine-enamine, annular tautomerism of heterocyclic rings such as pyrozole ring, and the like. Tautomeric forms are intended to be encompassed by compounds of formula (I), even though only one tautomeric form may be depicted.
Examples of preferred compounds of one group of formula (I) include
Compounds of the invention may be administered to a patient in therapeutically effective amounts which range usually from about 0.5 to about 2000 mg, more typically form about 1 to about 500 mg, for example from about 2 to about 100 mg, daily depending on the age, sex, weight, ethnic group, condition of the patient, condition to be treated, administration route and the active ingredient used. The compounds of the invention can be formulated into dosage forms using the principles known in the art. The compound can be given to a patient as such or in combination with suitable pharmaceutical excipients in the form of tablets, granules, capsules, suppositories, emulsions, suspensions or solutions. Choosing suitable ingredients for the composition is a routine for those of ordinary skill in the art. Suitable carriers, solvents, gel forming ingredients, dispersion forming ingredients, antioxidants, colours, sweeteners, wetting compounds and other ingredients normally used in this field of technology may also be used. The compositions containing the active compound can be given enterally or parenterally, the oral route being the preferred way. The contents of the active compound in the composition is from about 0.5 to 100%, typically from about 0.5 to about 20%, per weight of the total composition.
The compounds of the invention can be given to the subject as the sole active ingredient or in combination with one of more other active ingredients for treatment of a particular disease.
In the treatment of diseases and conditions wherein inhibition of TEAD is desired, such as various cancers or chronic pain, a combination of therapeutic agents and/or other treatments (e.g., radiation therapy) is often advantageous. The second (or third) agent to be administered may have the same or different mechanism of action than the primary therapeutic agent.
Accordingly, a compound of the invention may be administered in combination with other anti-cancer treatments useful in the treatment of cancers. For example, a compound of the invention can be packaged together with instructions that the compound is to be used in combination with other anti-cancer agents and treatments for the treatment of cancer. Similarly, a compound of the invention may be administered in combination with other pain reliever agents useful in the treatment of chronic pain. For example, a compound of the invention can be packaged together with instructions that the compound is to be used in combination with other anti-cancer agents and treatments for the treatment of cancer, or with other pain reliever agents and treatments for the treatment of chronic pain. The present invention further comprises combinations of a compound of the invention and one or more additional agents in kit form, for example, where they are packaged together or placed in separate packages to be sold together as a kit, or where they are packaged to be formulated together.
According to one embodiment of the invention, the therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof is co-administered with one or more anti-cancer agents or pain reliever agents.
The optional other anti-cancer agents which can be administered in addition to a compound of formula (I) or a pharmaceutically acceptable salt thereof include, but are not limited to,
According to still another embodiment, the present invention provides a pharmaceutical combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one additional active ingredient selected from the list consisting of
The above other therapeutic agents, when employed in combination with a compound of the invention can be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
The compounds of the invention can be prepared by a variety of synthetic routes analogously to the methods known in the literature using suitable starting materials. The present invention will be explained in more detail by the following experiments and examples. The experiments and examples are meant only for illustrating purposes and do not limit the scope of the invention defined in claims.
Purification methods used:
To a solution of 5-bromo-2-fluoro-4-methoxybenzaldehyde (1.000 g, 1 eq., 4.291 mmol) in CHCl3 (20 mL) was added 3-chlorobenzoperoxoic acid (1.851 g, 2.5 eq., 10.73 mmol) at 4° C. followed by stirring for 30 min. The mixture was diluted with water (50 ml) and the resulted mixture was extracted with ethyl acetate (3×10 mL). The organic layers were combined, washed with saturated solution of NaHCO3 (2×10 mL) and brine (10 ml), dried over sodium sulfate, filtered and concentrated to give the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 8.57 (s, 1H), 7.69 (dd, 1H), 7.29 (dd, 1H), 3.86 (d, 3H).
The following intermediates were prepared according to the procedure described for Intermediate 1 from the starting materials indicated in the Table. Where LCMS/GCMS data was not informative, the data is not shown.
Sodium hydroxide (1.606 g, 2.5 eq., 40.15 mmol) was added to a solution of 5-bromo-2-fluoro-4-methoxyphenyl formate (4.0 g, 1 eq., 16.06 mmol) in methanol (100 mL). The mixture was stirred at 25° C. for 12 h. Then the mixture was concentrated, diluted with 50 mL of water, acidified to pH 1 and extracted with ethyl acetate (3×30 mL). The combined organic phases were dried over Na2SO4 and concentrated. The crude product was purified twice by column chromatography using hexane-MTBE and chloroform-acetonitrile systems to give the title compound (1.4 g, 6.0 mmol, 37%, 95% purity). 1H NMR (500 MHz, DMSO-d6) δ: 9.66 (s, 1H), 7.12 (d, 1H), 7.04 (d, 1H), 3.73 (s, 3H).
The following intermediates were prepared according to the procedure described for Intermediate 4 from the starting materials indicated in the Table. Where LCMS/GCMS data was not informative, the data is not shown.
5-Methoxy-7-nitrobenzofuran-2-carboxylic acid (1 g, 1 eq., 4.22 mmol) and copper (201 mg, 0.75 eq., 3.16 mmol) were refluxed in quinoline (20 mL) for 30 min. After cooling to RT the mixture was filtered and the filtrate was poured to 2 N hydrochloric acid and filtered. The obtained precipitate was concentrated three times with acetonitrile to give the title compound (710 mg, 3.5 mmol). 1H NMR (500 MHz, DMSO-d6) δ: 8.20 (s, 1H), 7.66 (d, 1H), 7.10 (s, 1H), 3.86 (s, 3H).
1-Bromo-4-methoxy-2-nitrobenzene (0.272 g, 1.17 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (244 mg, 1.17 mmol) and potassium phosphate (746 mg, 3.52 mmol) were mixed in dioxane (4 mL) and water (0.4 mL) under argon atmosphere and the mixture was heated to 100° C. Then di(1-adamantyl)-n-butylphosphine (21.0 mg, 0.05 eq., 58.6 μmol) and (2′-amino-[1,1′-biphenyl]-2-yl)-((methylsulfonyl)oxy)palladium (21.7 mg, 0.05 eq., 58.6 μmol) were added and the mixture was stirred for 14 h at 100° C. After cooling to RT the mixture was concentrated in vacuum. The residue was dissolved in ethyl acetate (5 mL), washed with brine (2×5 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give crude title compound (0.2 g, 0.73 mmol) which was used in the next step without further purification. LCMS: m/z 234.2 [M+H]+.
3-(4-Methoxy-2-nitrophenyl)-1-methyl-1H-pyrazole (1.2 g, 1 eq., 5.145 mmol) was mixed with pyridine HCl (2.973 g, 5 eq., 25.73 mmol) followed by stirring at 200° C. for 30 h. After cooling to RT the reaction mass was poured into water (10 mL) and extracted with ethyl acetate (3×20 mL). Combined organic phases were dried over sodium sulfate, filtered and concentrated to give the title compound (0.90 g, 3.7 mmol). 1H NMR (400 MHz, DMSO-d6) δ: 10.42 (s, 1H), 7.70 (d, 1H), 7.54 (d, 1H), 7.10 (d, 1H), 7.05 (dd, 1H), 6.33 (d, 1H), 3.81 (s, 3H).
The following intermediate was prepared according to the procedure described for Intermediate 10b from the starting material indicated in the Table.
To a stirred solution of 4-fluoro-3-methoxyphenol (6 g, 1 eq., 42.21 mmol) and imidazole (5.748 g, 2 eq., 84.43 mmol) in DCM (60 mL) at RT was added chlorotriiso-propylsilane (8.546 g, 9.487 mL, 1.05 eq., 44.33 mmol). The mixture was stirred for 16 h and then poured into saturated aqueous NH4Cl (40 mL), followed by extraction with DCM (3×50 mL). The combined extracts were washed with brine (30 mL), dried over Na2SO4, and concentrated in vacuum to give the title compound (10.00 g, 30 mmol). 1H NMR (400 MHz, Chloroform-d) δ: 6.87 (dd, 1H), 6.48 (dd, 1H), 6.34 (dt, 1H), 3.82 (s, 3H), 1.23 (dh, 3H), 1.08 (d, 21H).
(4-Fluoro-3-methoxyphenoxy)triisopropylsilane (6.544 g, 1 eq., 21.93 mmol) and potassium 2-methylpropan-2-olate (2.706 g, 1.1 eq., 24.12 mmol) were mixed in THF (60 mL) under argon atmosphere and cooled to −78° C. Butyl lithium (1.545 g, 9.647 mL, 2.5 molar, 1.1 eq., 24.12 mmol) was added dropwise at −78° C. Then the mixture was stirred for 1 h at the same temperature. The solution of iodine (6.678 g, 1.2 eq., 26.31 mmol) in THF (20 mL) was added dropwise at −78° C. After stirring at RT overnight, the mixture was cooled to −20° C. and aqueous solution of ammonium chloride (20 mL) was added dropwise. Then the solution was warmed to RT. EtOAc (70 mL) was added and the organic layer was washed with brine (2×30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (hexane/MTBE) to give the title compound (2.0 g, 3.3 mmol). GCMS: m/z 424 [M]+.
(4-Fluoro-3-iodo-5-methoxyphenoxy)triisopropylsilane (2.3 g, 1 eq., 5.420 mmol) was dissolved in THF (10 mL) and tetrabutylammonium fluoride (3.543 g, 13.55 mL, 1 molar, 2.5 eq., 13.55 mmol) was added dropwise. The mixture was stirred at RT for 16 h and then concentrated in vacuum. The residue was dissolved in EtOAc (20 mL), washed with water (2×5 mL), dried under sodium sulfate and concentrated in vacuum. The obtained residue was purified by flash chromatography (hexane/MTBE) to give the title compound (0.575 g, 1.9 mmol). 1H NMR (400 MHz, Chloroform-d) δ: 6.72 (t, 1H), 6.45 (dd, 1H), 4.86 (s, 1H), 3.82 (s, 3H).
4-Methoxy-3-nitrophenol (1 g, 1 Eq., 6 mmol), (4-(trifluoromethyl)phenyl)-boronic acid (2 g, 2 eq., 0.01 mol), pyridine (0.9 g, 1 mL, 2 eq., 0.01 mol), diacetoxycopper (1 g, 1.05 eq., 6 mmol) and powdered molecular sieves 4 Å (1 g) were suspended in dichloromethane (10 mL). The air was bubbled through the resulting solution for 30 min and the mixture was stirred at RT overnight. The mixture was filtered. The filtrate was washed with water (2×30 mL), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by method A to afford the title compound. LCMS: m/z 314.0 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 13 from the starting materials indicated in the Table. Where LCMS/GCMS data was not informative, the data is not shown.
1-Fluoro-2-methoxy-4-(4-(trifluoromethyl)phenoxy)benzene (4.000 g, 1 eq., 13.97 mmol) and potassium 2-methylpropan-2-olate (1.725 g, 1.1 eq., 15.37 mmol) were mixed in THF (60 mL) and cooled to −78° C. under argon atmosphere. Butyl lithium (984.7 mg, 6.149 mL, 2.5 molar, 1.1 eq., 15.37 mmol) was added dropwise at −78° C. and the mixture was stirred for 2 h at the same temperature. A solution of iodine (4.256 g, 1.2 eq., 16.77 mmol) in THF (20 mL) was added dropwise at −78° C. After stirring at RT overnight, the mixture was cooled to −20° C. and aqueous solution of ammonium chloride (10 mL) was added dropwise. Then the solution was warmed to RT. EtOAc (100 mL) was added and the organic layer was washed with brine (2×25 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (hexane/MTBE) to give the title compound (0.900 g, 2.0 mmol, 14%, 90% purity).
6-Bromo-8-nitrochroman-4-one (2.00 g, 1 eq., 7.35 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.24 g, 1.2 eq., 8.82 mmol) and potassium acetate (2.16 g, 3 eq., 22.1 mmol) were mixed in 1,4-dioxane (20 mL). Argon was bubbled into the solution at 25° C. for 1 h to remove any excess oxygen. PdCl2(dppf)CH2Cl2 (180 mg, 0.03 eq., 221 μmol) was added to the mixture under argon atmosphere. The mixture was heated to 80° C. and stirred for 3 h until the reaction was completed. The mixture was cooled to 25° C. and then filtered. The precipitate was washed with dioxane (15 mL). The filtered solutions were combined, concentrated and then transferred to a reactor. Hydrogen peroxide (4.29 g, 4.29 mL, 35 w-%, 6 eq., 44.1 mmol) was added and the mixture was heated to 50° C. and stirred for 40 min until the reaction was completed. Water (10 mL) was added to the mixture, and the mixture was extracted with DCM (2×50 mL). The organic phase was collected, washed with 15% brine (2×15 mL) and extracted with 15% Na2CO3 (2×25 mL). The aqueous phase was collected and the pH value was adjusted to 4-5 with 3 M HCl. The aqueous phase was then extracted with ethyl acetate (2×50 mL). The organic phase was collected, dried over Na2SO4 and concentrated under reduced pressure to obtain the title compound (810 mg, 3.6 mmol). LCMS: m/z 208.0 [M+H]+
The following intermediate was prepared according to the procedure described for Intermediate 49 from the starting material indicated in the Table.
7-Nitrobenzo[d][1,3]dioxole-5-carbaldehyde (1000 mg, 1 eq., 5.125 mmol) was dissolved in anhydrous methanol (40 mL). The mixture was cooled to 0° C. and sodium borohydride (232.6 mg, 1.2 eq., 6.150 mmol) was added portionwise during 10 min. The mixture was stirred at RT for 18 h and then concentrated under reduced pressure. The resulting residue was treated with saturated ammonium chloride solution (30 mL), extracted with ethyl acetate (3×20 mL), dried over anhydrous sodium sulphate, and concentrated under reduced pressure to give the title compound (0.693 g, 3.29 mmol, 64.1%, 93.46% purity). 1H NMR (500 MHz, DMSO-d6) δ: 7.50 (s, 1H), 7.21 (s, 1H), 6.28 (s, 2H), 5.41 (s, 1H), 4.45 (s, 2H).
The following intermediates were prepared according to the procedure described for Intermediate 51 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
2,4-Dimethoxy-1-nitrobenzene (1 g, 1 eq., 5 mmol), formaldehyde (0.3 g, 2 eq., 0.01 mol, aq. 40%) and zinc (II) chloride (0.07 g, 0.1 eq., 0.5 mmol) were dissolved in aqueous (37%) hydrochloric acid (10 mL) followed by stirring at 100° C. for 12 h. After cooling to RT the reaction mixture was extracted with dichloromethane (2×50 mL), organic layers were combined, washed with water (2×100 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give crude title compound (312 mg, 1.46 mmol, 30%, 100% purity), which was purified by method A. 1H NMR (400 MHz, DMSO-d6) δ: 7.97 (s, 1H), 6.81 (d, 1H), 4.43 (d, 2H), 4.01 (d, 1H), 3.96 (dd, 6H).
The following intermediate was prepared according to the procedure described for Intermediate 56 from the starting material indicated in the table.
(3-Fluoro-4-methoxy-5-nitrophenyl)methanol (610 mg, 1 eq., 3.03 mmol) was dissolved in DCM (7 mL) and DMF (2.22 mg, 2.35 μL, 0.01 eq., 30.3 μmol) was added. The resulting solution was cooled to 0° C. and thionyl chloride (722 mg, 443 μL, 2 eq., 6.07 mmol) was added dropwise to the mixture at the same temperature and the solution was stirred at 0° C. for 10 min followed by warming to RT and stirring at this temperature overnight. The solution was then poured into 10% aqueous sodium bicarbonate solution (10 mL) and stirred for 10 min. Then the aqueous layer was extracted with DCM (10 mL). Combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated under vacuum to give the title compound (602 mg, 2.4 mmol, 80%, 88% purity), which was used in the next step without further purification. LCMS: m/z 219.8 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 58 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
To a solution of tert-butyl (3-fluorophenyl)carbamate (1.048 g, 1 eq., 4.960 mmol) in DMF (20 mL) at 0° C. sodium hydride (238.1 mg, 60%, 1.2 eq., 5.952 mmol) was added and the mixture was stirred at RT for 30 min. 4-(Chloromethyl)-1-methoxy-2-nitrobenzene (1.000 g, 1 eq., 4.960 mmol) was added in a single portion and the mixture was stirred at RT for 18 h. The resulting mixture was filtered, and the filtrate was diluted with water (50 mL) and ethyl acetate (50 mL). Layers were separated, the organic phase was washed with brine (4×30 mL), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure, to afford the title compound, which was used in the next step without further purification.
The following intermediates were prepared according to the procedure described for Intermediate 62 from the starting materials indicated in the table.
3,4-Difluorophenol (2.00 g, 1 eq., 15.4 mmol) was dissolved in DMF (20 mL), sodium hydride (676 mg, 60%, 1.1 eq., 16.9 mmol) was added at RT and the mixture was stirred at this temperature for 30 min 4-(Chloromethyl)-1-methoxy-2-nitrobenzene (3.41 g, 1.1 eq., 16.9 mmol) was added and the mixture was heated at 100° C. for 16 h. The solution was cooled to RT and concentrated. The residue was taken up in ethyl acetate (60 mL). The resulting solution was washed with brine (3×50 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (4.5 g, 14 mmol, 94%, 95% purity). The crude product was used in the next step without further purification.
The following intermediates were prepared according to the procedure described for Intermediate 69 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
1,2,4-Trifluorobenzene (2.4 g, 1 eq., 18 mmol), 4-methoxy-3-nitrophenol (3.1 g, 1 eq., 18 mmol) and potassium 2-methylpropan-2-olate (2.2 g, 1.1 eq., 20 mmol) were dissolved in DMF (50 mL) and the resulting mixture was stirred at 80° C. for 10 h. Then EtOAc (50 mL) was added and the organic layer was washed with brine (5×30 mL), dried and evaporated under reduced pressure to afford title compound, which was used in the next step without further purification. GCMS: m/z 281 [M]+
5-Bromo-2-methoxyaniline (730 mg, 1 eq., 3.61 mmol), (E)-4,4,5,5-tetramethyl-2-(2-(tetrahydro-2H-pyran-4-yl)vinyl)-1,3,2-dioxaborolane (1.29 g, 1.5 eq., 5.42 mmol), sodium carbonate (383 mg, 1 eq., 3.61 mmol) and PdCl2(dppf)-CH2Cl2 adduct (295 mg, 0.1 eq., 361 μmol) were suspended in degassed 1,4-dioxane (12 mL) and water (2.4 mL). The mixture was heated under argon at 90° C. overnight. After cooling to RT the solvent was evaporated in vacuum, the residue was dissolved in ethyl acetate (30 mL), washed with brine (20 mL), dried over sodium sulfate, filtered, concentrated in vacuum and the residue was purified by method A to give the title compound (205 mg, 839 μmol, 23.2%, 95.5% purity). LCMS: m/z 234.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 76 from the starting materials indicated in the table.
7-Bromo-2,3-dihydrobenzofuran-5-ol (0.500 g, 1 eq., 2.33 mmol) was dissolved in N,N-Dimethylformamide (5 mL) and cesium carbonate (1.52 g, 2 eq., 4.65 mmol) was added. The mixture was stirred at RT for 10 min and 4-(chloromethyl)-1,2-difluoro-benzene (378 mg, 1 eq., 2.33 mmol) was added. The mixture was stirred at RT for 12 h. The resulting solution was concentrated under reduced pressure. The residue was taken up in ethyl acetate (20 mL). The obtained solution was washed with brine (20 mL), water (20 mL), dried over sodium sulfate, filtered and evaporated to afford the title compound. The crude product was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ: 7.22-7.02 (m, 3H), 6.85 (s, 1H), 6.75 (s, 1H), 4.90 (s, 2H), 4.61 (t, 2H), 3.26 (t, 2H).
The following intermediates were prepared according to the procedure described for Intermediate 78 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
1-(Chloromethyl)-2-fluoro-4-methoxy-5-nitrobenzene (0.306 g, 1 eq., 1.39 mmol) was dissolved in acetonitrile (3 mL), cesium carbonate (908 mg, 2 eq., 2.79 mmol) and sodium iodide (209 mg, 1 eq., 1.39 mmol) were added. The mixture was stirred for 10 min and 3-fluorophenol (141 mg, 114 μL, 0.9 eq., 1.25 mmol) was added. The mixture was stirred at RT for 10 h. The resulting solution was filtered and concentrated to give the title compound (0.362 g, 0.61 mmol, 44%, 50% purity), which was used in the next step without further purification. LCMS: m/z 297.2 [M+H]+
1,5-Difluoro-2-nitro-4-(3-(trifluoromethyl)phenoxy)benzene (150 mg, 1 eq., 470 μmol) was dissolved in toluene (2 mL). The solution was cooled to 0° C., then methanol (15.1 mg, 19.0 μL, 1 eq., 470 μmol) was added at 0° C. To the obtained solution potassium tert-butoxide (52.7 mg, 1 eq., 470 μmol) was added at 0° C. The mixture was stirred at 0° C. for 10 minutes, then temperature was raised to RT followed by stirring for 12 h. The reaction mixture was quenched with water (15 mL) followed by stirring for 15 minutes. Toluene (10 mL) was added to the mixture. The layers were separated, and the aqueous layer was extracted with toluene (2×10 mL). Combined organic layers were washed with water (20 mL), brine (20 mL) and dried over sodium sulfate. The solvent was evaporated under reduced pressure to afford the title compound which was used in next step without further purification. GCMS: m/z 331.0 [M]+.
A solution of (7-bromobenzofuran-5-yl)methanol (3.110 g, 1 eq., 13.70 mmol) and triphenylphosphine (4.311 g, 1.2 eq., 16.44 mmol) in THF (100 mL) was cooled to 0° C. under inert atmosphere. Diethyl (E)-diazene-1,2-dicarboxylate (2.863 g, 2.58 mL, 1.2 eq., 16.44 mmol) was slowly added and the mixture was stirred for 30 min followed by addition of 3-fluorophenol (1.612 g, 1.302 mL, 1.05 eq., 14.38 mmol). The ice-bath was removed and the mixture was stirred at RT for 17 h. The THF was evaporated, and the mixture was dissolved in MTBE (10 mL), washed with NaOH (3 mL, 10%) and water (3 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash-chromatography (MTBE/hexane, flow rate 30 mL/min) to give the title compound (1.42 g, 4.2 mmol, 31%, 95% purity). 1H NMR (400 MHz, DMSO-d6) δ: 8.03 (s, 1H), 7.72 (s, 1H), 7.59 (s, 1H), 7.33-7.23 (m, 1H), 7.03 (d, 1H), 6.83 (d, 2H), 6.75-6.65 (m, 1H), 5.17 (s, 2H).
The following intermediates were prepared according to the procedure described for Intermediate 86 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
4-Methoxy-3-nitrophenol (5.00 g, 1 eq., 29.6 mmol), triphenylphosphine (15.5 g, 2 eq., 59.1 mmol) and bicyclo[2.2.1]heptan-2-ol (3.32 g, 1 eq., 29.6 mmol) were dissolved in THF (50 mL). The mixture was cooled to 4° C. and diisopropyl diazene-1,2-dicarboxylate (12.0 g, 11.5 mL, 2 eq., 59.1 mmol) was added. The mixture was stirred at RT for 16 h, then concentrated and purified by flash-chromatography (MTBE/hexane, flow rate 30 mL/min) to afford the title compound.
The following intermediate was prepared according to the procedure described for Intermediate 97 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
2,4-Difluoro-1-(4-methoxyphenoxy)benzene (0.180 g, 1 eq., 762 μmol) was dissolved in acetic acid (1 mL) and the solution was cooled to 0° C. Then nitric acid (144 mg, 102 μL, 3 eq., 2.29 mmol) was added to the mixture dropwise and the resulting solution was stirred at RT for 10 h. Then the mixture was poured into ice-cooled saturated sodium carbonate solution (5 mL) and EtOAc (5 mL) was added. The organic layer was separated, dried over sodium sulfate and concentrated in vacuum to afford the title compound, which was used in the next step without further purification. GCMS: m/z 281 [M]+
8-Nitrochromane-4,6-diol (135 mg, 1 eq., 639 μmol) was dissolved in TFA (2 mL) and triethylsilane (372 mg, 0.511 mL, 5.00 eq., 3.20 mmol) was added. The mixture was stirred at 23° C. for 16 h, than concentrated, mixed with hexane (10 mL) and filtered. Obtained precipitate was dried under reduced pressure to give the title compound (100 mg, 0.49 mmol). The crude product was used in the next step without further purification. LCMS: m/z 196.0 [M+H]+
7-Bromo-5-methoxy-1H-benzo[d]imidazole (0.3 g, 1 eq., 1.32 mmol) was dissolved in DMF (5 mL). The mixture was cooled to 5° C. and sodium hydride (58.1 mg, 60 w-%, 1.1 eq., 1.45 mmol) was added in portions. The mixture was stirred at 5° C. for 30 min and methyl iodide (206 mg, 90.9 μL, 1.1 eq., 1.45 mmol) was added dropwise at the same temperature. The resulting mixture was heated to 20° C. and stirred for 12 h, poured into ice-cooled water (10 mL) and extracted with EtOAc (2×20 mL). The combined organic layers were washed with brine (4×5 mL), dried and concentrated to give a mixture of crude products, which were separated by HPLC (Method A) to give two regioisomers 7-bromo-5-methoxy-1-methyl-1H-benzo[d]imidazole (0.0467 g, 194 μmol) and 4-bromo-6-methoxy-1-methyl-1H-benzo[d]imidazole (0.0868 g, 360 μmol). LCMS: m/z 243.0 [M+H]+.
4-Bromo-6-methoxy-1-methyl-1H-benzo[d]imidazole (80 mg, 1 eq., 0.33 mmol) was dissolved in DCM (2 mL) and tribromoborane (0.83 g, 0.32 mL, 10 eq., 3.3 mmol) was added to the mixture dropwise at 4° C. The resulting mixture was stirred at 28° C. for 18 h and the MeOH (5 mL) was added to the mixture at 4° C. dropwise. The mixture was concentrated under reduced pressure and the residue was poured into saturated aqueous sodium carbonate solution (10 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layer was dried over sodium sulfate and concentrated to give crude 4-bromo-1-methyl-1H-benzo[d]imidazol-6-ol (80 mg, 0.26 mmol) which was used in the next step without further purification. LCMS: m/z 227.0 [M+H]+
The mixture of 5-bromo-2-fluoro-4-methoxyphenol (4.75 g, 1 eq., 21.49 mmol), 2-fluoro-5-(trifluoromethyl)pyridine (3.548 g, 1 eq., 21.49 mmol) and cesium carbonate (14 g, 2 eq., 42.98 mmol) in DMF (100 mL) was stirred at 60° C. for 18 h. Water (100 mL) was added to the residue and the resulted mixture was extracted with ethyl acetate (100×20 mL). Organic layers were combined, washed with brine (4×100 mL), dried over sodium sulfate, filtered and evaporated to give crude title compound (6.35 g, 14.8 mmol) which was used in the next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ: 8.38 (s, 1H), 7.91 (dd, 1H), 7.42 (d, 1H), 7.07 (d, 1H), 6.78 (d, 1H), 3.88 (s, 3H).
Methyl 4-fluoro-2-nitrobenzoate (5.0 g, 1 eq., 25.11 mmol), 3,4-difluorophenol (3.593 g, 1.1 eq., 27.62 mmol) and potassium carbonate (6.940 g, 2 eq., 50.22 mmol) were mixed in acetonitrile (100 mL) followed by heating at reflux temperature for 14 h. After cooling to RT, the mixture was concentrated under reduced pressure, extracted with EtOAc (100 mL) and washed with water (20 mL), K2CO3 solution (20 mL, 15% in water) and brine (20 mL). The organic phase was dried over Na2SO4 and concentrated in vacuum to give the title compound (6.68 g, 19 mmol, 77%, 90% purity). 1H NMR (500 MHz, DMSO-d6) δ: 7.89 (d, 1H), 7.63 (d, 1H), 7.59-7.50 (m, 1H), 7.47 (dq, 1H), 7.33 (dd, 1H), 7.12-7.03 (m, 1H), 3.81 (s, 3H).
The following intermediates were prepared according to the procedure described for Intermediate 105 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
To a solution of the methyl 4-(3,4-difluorophenoxy)-2-nitrobenzoate (2.000 g, 1 eq., 6.468 mmol) in ethanol (20 mL) was added hydrazine hydrate (2.266 g, 7 eq., 45.28 mmol). The mixture was heated under reflux overnight. Then the solvent was evaporated under reduced pressure, and water (20 mL) was added to the residue. The obtained solid was filtered, washed with water, hexane and dried in vacuum to give the title compound (1.900 g, 5.5 mmol, 85%, 90% purity). 1H NMR (500 MHz, DMSO-d6) δ: 9.77 (s, 1H), 7.59 (d, 1H), 7.59-7.49 (m, 2H), 7.47-7.42 (m, 1H), 7.33 (dd, 1H), 7.07-6.99 (m, 1H), 4.32 (s, 1H).
The following intermediates were prepared according to the procedure described for Intermediate 116 from the starting materials indicated in the table.
4-(3,4-Difluorophenoxy)-2-nitrobenzohydrazide (1.000 g, 1 eq., 3.234 mmol), 4-methylbenzenesulfonic acid (111.4 mg, 0.2 eq., 646.8 μmol) and triethoxymethane (20 mL) were heated at reflux temperature for 14 h. The mixture was then concentrated in vacuum to give the title compound (1.00 g, 2.2 mmol, 69%, 71% purity) LCMS: m/z 320.0 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 119 from the starting materials indicated in the table.
A solution of 1-(4-(3,4-difluorophenoxy)-2-nitrophenyl)ethan-1-one (0.300 g, 1 eq., 1.02 mmol), DMF-DMA (244 mg, 272 μL, 2 Eq, 2.05 mmol) and toluene (3 mL) was stirred and heated at reflux temperature for 16 h followed by cooling to RT. The resulting solid was filtered, washed with toluene, hexane and dried in vacuum to afford the title compound (0.246 g, 706 μmol, 69.0%) as a yellow solid. LCMS: m/z 349.2 [M+H]+.
(E)-1-(4-(3,4-Difluorophenoxy)-2-nitrophenyl)-3-(dimethylamino)prop-2-en-1-one (0.246 g, 1 eq., 706 μmol) and methylhydrazine sulfate (112 mg, 1.1 eq., 777 μmol) were mixed in 2-propanol (4 mL) and heated at reflux temperature for 18 h. The mixture was cooled to RT, concentrated in vacuum and purified by method C to give the title compound (0.109 g, 329 μmol, 46.6%, 100% purity). LCMS: m/z 332.0 [M+H]+.
To a stirred solution of 2-methyl-6-nitro-4-((5-(trifluoromethyl)pyridin-2-yl)-oxy)aniline (1.524 g, 1 eq., 4.865 mmol) in acetic acid (70.5 mL), a solution of sodium nitrite (369.2 mg, 1.1 eq., 5.352 mmol) in water (2.4 mL) was added and the mixture was stirred for 1 h. After completion of the reaction, acetic acid was distilled off and the obtained residue was mixed with ice water (200 mL) and extracted with MTBE (3×30 mL). The combined organic phase was washed with water (2×10 mL), dried under sodium sulfate and concentrated under reduced pressure to yield the title compound (1.5 g, 3.9 mmol, 80%, 84% purity). LCMS: m/z 325.0 [M+H]+.
The following intermediate was prepared according to the procedure described for Intermediate 124 from the starting material indicated in the table.
5-(2-Chloro-4-(trifluoromethyl)phenoxy)-7-nitro-1H-indazole (0.093 g, 1 eq., 0.26 mmol) was dissolved in methanol (15 mL). Formic acid, ammonia salt (0.33 g, 20 eq., 5.2 mmol) and palladium (0.22 g, 10 w-%, 0.8 eq., 0.21 mmol) were added. The resulting mixture was stirred at 65° C. for 16 h, cooled to RT and filtered. The filtrate was concentrated under reduced pressure and treated with EtOAc (10 mL). The precipitate was filtered and dried under reduced pressure to give the title compound (0.044 g, 0.15 mmol, 58%, 100% purity) which was used in the next step without further purification. 1H NMR (500 MHz, DMSO-d6) δ: 7.87 (s, 1H), 7.65 (d, 2H), 7.06 (d, 2H), 6.62 (s, 1H), 6.18 (s, 1H), 5.69 (s, 2H).
To a solution of 7-nitro-5-((5-(trifluoromethyl)pyridin-2-yl)oxy)-1H-indazole (0.1 g, 1 eq., 308 μmol) in THF (4 mL) cooled to 0° C. sodium hydride (14.8 mg, 60 w-%, 1.2 eq., 370 μmol) was added. After stirring for 1 h at 23° C., methyl iodide (46.0 mg, 20.3 μL, 1.05 eq., 324 μmol) was added dropwise at 0° C. The mixture was stirred for 16 h at 23° C. Water (1 mL) was added and the resulting mixture was concentrated under reduced pressure. The crude material was dissolved in EtOAc (10 mL), washed with water and brine, dried over MgSOs and the solvent removed under reduced pressure to give the title compound (0.129 g, 310 μmol, 100%, 81.2% purity), which was used in the next step without further purification. LCMS: m/z 339.2 [M+H]+.
A mixture of 1-Bromo-4-methoxy-2-methyl-3-nitrobenzene (0.384 g, 1.5 mmol), 3,4-difluorophenol (0.13 g, 1.0 mmol), Cs2CO3 (0.652 g, 2.0 mmol), CuI (0.057 g, 0.3 mmol) and N,N-dimethylglycine (0.031 g, 0.3 mmol) in dioxane (5 ml) was heated at 130° C. for 24 hours. The mixture was evaporated and the residue was purified by normal phase chromatography to yield 0.175 g of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 2.07 (3H, s), 3.87 (3H, s), 6.71-6.79 (1H, m), 7.12-7.19 (1H, m), 7.19-7.27 (2H, m), 7.38-7.49 (1H, m).
1-Methoxy-2-nitro-4-(4-(trifluoromethyl)phenoxy)benzene (558 mg, 1 eq., 1.78 mmol) was dissolved in methanol (20 mL) and treated with Pd/C (37.9 mg, 0.2 eq., 356 μmol). The resulting mixture was hydrogenated at 1 atm pressure at RT overnight. The catalyst was filtered off and the solvent was evaporated under reduced pressure to afford the crude title product which was used in the next step without further purification. LCMS: m/z 284.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 129 from the starting material indicated in the table.
A mixture of 2-chloro-4-(trifluoromethyl)pyridine (2.72 g, 15.0 mmol), 4-methoxy-3-nitrophenol (2.80 g, 15.8 mmol) and Cs2CO3 (5.68 g, 17.3 mmol) in DMF (20 ml) was heated at 100° C. for 7 h. Water was added (50 ml) and the mixture was extracted with EtOAc (3×50 ml). The organic layers were combined and evaporated to yield 4.71 g of the crude title compound which was used in the next reaction without further purification. 1H NMR (400 MHz, DMSO-d6) δ: 3.96 (3H, s), 7.44 (1H, d), 7.50-7.59 (3H, m), 7.84 (1H, d), 8.41 (1H, d). LCMS: m/z 315.4 [M+H]+
The following intermediates were prepared according to the procedure described for Intermediate 158 from the starting material indicated in the table.
1-Methoxy-2-nitro-4-((3-(trifluoromethyl)benzyl)oxy)benzene (8.70 g, 1 eq., 26.6 mmol), water (7.43 g, 7.4 mL, 15.5 eq., 412 mmol), ammonia hydrochloride (142 mg, 0.1 eq., 2.66 mmol) and hydrogen chloride (266 mg, 226 μL, 36.5% aqueous, 0.1 eq., 2.66 mmol) were mixed in 1,4-dioxane (200 mL) followed by addition of iron (7.42 g, 5 eq., 133 mmol). The mixture was stirred at 110° C. for 5 h and at RT for 16 h. The mixture was filtered through thin layer of silica, concentrated and the residue was added to dioxane saturated with hydrochloric acid (30 mL). The solution was evaporated under reduced pressure. The obtained residue was washed with ethyl acetate and dried to give the title compound. LCMS: m/z 334.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 163 from the starting material indicated in the table.
5-Chloro-2-(4-methoxy-3-nitrophenoxy)pyridine (197 mg, 1 eq., 702 μmol) was dissolved in methanol (5 mL) and platinum (20.5 mg, 0.15 eq., 105 μmol) was added. The mixture was degassed and stirred in atmosphere of hydrogen for 12 h, then filtered and the solvent was evaporated to give the title compound (175 mg, 0.66 mmol, 94%, 95% purity) which was used in next step without further purification. LCMS: m/z 251.0 [M+H]+.
4-Bromo-6-(3-(trifluoromethyl)phenoxy)benzo[d][1,3]dioxole (1.20 g, 1 eq., 3.32 mmol), diphenylmethanimine (663 mg, 1.1 eq., 3.66 mmol), sodium 2-methyl-propan-2-olate (335 mg, 1.05 eq., 3.49 mmol) and 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (207 mg, 0.1 eq., 332 μmol) were dissolved in toluene (20 mL). The solution was bubbled with argon for 1 min, then diacetoxy palladium (37.3 mg, 0.05 eq., 166 μmol) was added and the mixture was stirred at 110° C. for 12 h in argon atmosphere. The mixture was filtered and the solid was washed with ethyl acetate (2×20 mL). Then ethyl acetate solution was washed with brine (2×50 mL). The organic phase was dried over sodium sulfate and filtered. Solvent was evaporated under reduced pressure to give title compound which was used in the next step without further purification. LCMS: m/z 462.0 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 183 from the starting material indicated in the table.
To a mixture of 5-bromo-7-(4-(trifluoromethyl)phenoxy)-2,3-dihydrobenzo[b]-[1,4]dioxine (1.410 g, 1 eq., 3.759 mmol), tert-butyl carbamate (660.5 mg, 1.5 eq., 5.638 mmol) and cesium carbonate (3.674 g, 3 eq., 11.28 mmol) in toluene (40 mL) under argon XantPhos (326.2 mg, 0.15 eq., 563.8 μmol) and tris(dibenzylideneacetone)-dipalladium (172.1 mg, 0.05 eq., 187.9 μmol) were added and the mixture was heated at 110° C. for 18 h. After cooling to RT the mixture was filtered and concentrated. The residue was diluted with ethyl acetate (10 mL) and washed with brine (2×50 mL). The organic phase was dried over Na2SO4, filtered and concentrated in vacuum. The residue was recrystallized from acetonitrile to give the title compound. LCMS: m/z 412.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 189 from the starting materials indicated in the table. Where LCMS/GCMS data was not informative, the data is not shown.
Chlorotrimethylsilane (1.320 g, 1.54 mL, 5 eq., 12.15 mmol) was added to methanol (25 mL) at 0° C. dropwise. The mixture was stirred for 30 min and tert-butyl (7-(4-(trifluoromethyl)phenoxy)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)carbamate (1 g, 1 eq., 2.431 mmol) was added and this solution was stirred at RT for 48 h. The mixture was concentrated in vacuum to give crude title compound (808 mg, 2.11 mmol, 86.9%, 90.93% purity). LCMS: m/z 312.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 202 from the starting material indicated in the table.
1,1-Diphenyl-N-(6-(3-(trifluoromethyl)phenoxy)benzo[d][1,3]dioxol-4-yl)-methanimine (0.800 g, 1 eq., 1.73 mmol) was dissolved in THF (10 mL) and HCl solution (253 mg, 6.93 mL, 1 molar, 4 eq., 6.93 mmol) was added at RT. A mixture was stirred at RT for 10 mi and then evaporated in vacuum to give the title compound (640 mg, 1.1 mmol, 62%, 50% purity) which was used in the next step without further purification. LCMS: m/z 298.0 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 214 from the starting material indicated in the table.
tert-Butyl (5-(2-chloro-4-(trifluoromethyl)phenoxy)-4-fluoro-2-methoxy-phenyl)carbamate (0.185 g, 1 eq., 425 μmol) was dissolved in methanol (5 mL) and the solution of HCl (155 mg, 104 μL, 10 w-%, 1 eq., 425 μmol) in dioxane was added dropwise at 25° C. The mixture was stirred at 25° C. for 56 h and then concentrated under reduced pressure to give the title compound (0.150 g, 0.32 mmol, 76%, 80% purity) which was used in the next step without further purification. 1H NMR (500 MHz, DMSO-d6) δ: 8.00 (s, 1H), 7.66 (d, 1H), 7.21 (d, 1H), 6.97 (m, 2H), 3.85 (s, 3H). LCMS: m/z 336.0 [M+H]+.
Methyl alaninate 1,1-dioxide (350 mg, 1 eq., 2.12 mmol) and potassium carbonate (879 mg, 3 eq., 6.36 mmol) were mixed in anhydrous DMF (5 mL) followed by adding iodomethane (1.50 g, 660 μL, 5 eq., 10.6 mmol) in a single portion. The mixture was stirred at 27° C. for 18 h. The mixture was concentrated in vacuum, the residue was treated with water (5 mL) and the obtained suspension was extracted with ethyl acetate (2×20 mL). Combined organic phases were washed with brine (2×15 mL), dried over sodium sulfate, filtered and concentrated in vacuum to give the title compound (116 mg, 0.39 mmol, 18%, 60% purity) which was used in the next step without further purification. 1H NMR (500 MHz, DMSO-d6) δ: 4.56-4.46 (m, 1H), 4.38 (m, 1H), 3.95 (m, 1H), 3.71 (s, 3H), 2.67 (s, 3H).
Methyl N-methylalaninate 1,1-dioxide (100 mg, 1 eq., 558 μmol) and lithium hydroxide hydrate (23.4 mg, 1 eq., 558 μmol) were dissolved in methanol (2 mL) and stirred at RT for 16 h. The mixture was concentrated and the residue was concentrated three times with acetonitrile to give the title compound (77 mg, 0.43 mmol, 77%, 95% purity) which was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6) δ: 4.10-3.96 (m, 2H), 3.13 (t, 1H), 2.61 (s, 3H).
To a solution of tert-butyl 1-methyl-5-oxopyrrolidine-2-carboxylate (470 mg, 1 eq., 2.36 mmol) in THF (3 mL) phosphorus (V) sulfide (262 mg, 0.5 eq., 1.18 mmol) was added. The mixture was refluxed with stirring for 24 h. The solution was cooled and filtered. Chloroform (20 mL) was added, and the organic phase was washed with saturated sodium hydrocarbonate, (20 mL). The aqueous phase was extracted with chloroform (20 mL). The combined organic phases were dried and concentrated under vacuum to give the title compound (500 mg, 1.8 mmol, 76%, 77% purity) which was used in next step without further purification. GCMS: m/z 216.1 [M]+.
tert-Butyl 1-methyl-5-thioxopyrrolidine-2-carboxylate (500 mg, 1 eq., 2.32 mmol) was dissolved in trifluoroacetic acid (2.65 g, 1.79 mL, 10 eq., 23.2 mmol) and the solution was stirred at RT for 12 h. Then the solvent was evaporated and the residue was dissolved in toluene (5 mL) and concentrated to remove excess of TFA to give the title compound (370 mg, 1.2 mmol, 50%, 50% purity) which was used in the next step without further purification.
1-Methyl-5-oxopyrrolidine-2-carboxylic acid (0.5 g, 1.2 eq., 3.49 mmol) was dissolved in N,N-dimethylformamide (5 mL) and HATU (1.33 g, 1.2 eq., 3.49 mmol) was added. The solution was stirred for 5 min at RT. To this solution, 3-amino-4-methoxyphenol hydrochloride (511 mg, 1 eq., 2.91 mmol) was added, followed by the addition of DIPEA (1.05 g, 1.42 mL, 2.8 eq., 8.15 mmol). The mixture was then stirred at RT for 2 h. The solvent was removed in vacuum. The crude material was dissolved in ethyl acetate (10 mL), washed with brine (50 mL) and water (50 mL), dried and the solvent was evaporated. The residue was purified using method B to give the title compound (0.0667 g). 1H NMR (400 MHz, DMSO-d6) δ: 9.34 (s, 1H), 8.96 (s, 1H), 7.54 (s, 1H), 6.85 (d, 1H), 6.45 (d, 1H), 4.42 (d, 1H), 3.32 (s, 2H), 2.66 (s, 3H), 2.37-2.11 (m, 3H), 1.87 (s, 1H). LCMS: m/z 265.2 [M+H]+.
The following intermediate was prepared according to the procedure described for Intermediate 223 from the starting material indicated in the table.
To a mixture of tert-butyl (3-amino-4-methoxybenzyl)(3-fluorophenyl)carbamate (200 mg, 1 eq., 577 μmol), 5-oxopyrrolidine-2-carboxylic acid (74.5 mg, 1 eq., 577 μmol) and 1-methyl-1H-imidazole (237 mg, 5 eq., 2.89 mmol) in acetonitrile (4 mL) was added N-(chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate(V) (243 mg, 1.5 eq., 866 μmol). The mixture was stirred at RT for 18 h and then concentrated in vacuum. Water (20 mL) was added to the residue and the resulted mixture was extracted with ethyl acetate (2×20 mL). Organic layers were combined, washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (0.3 g) which was used in the next step without further purification. LCMS: m/z 358.0 [M+H]+.
To the solution of methyl 4-hydroxy-2,3-dihydrobenzofuran-6-carboxylate (2 g, 1 eq., 10.30 mmol) and N-ethyl-N-isopropylpropan-2-amine (3.994 g, 5.38 mL, 3 eq., 30.90 mmol) in DCM (80 mL) chloro(methoxy)methane (1.309 g, 1.24 mL, 95 w-%, 1.5 eq., 15.45 mmol) was added at 0° C. followed by stirring the mixture at 20° C. for 18 h. The mixture was washed with brine (3×10 mL), dried over sodium sulfate, filtered and evaporated to afford the title compound (2.3 g, 8.834 mmol, 85.78%, 90.75% purity) which was used in the next step without further purification. 1H NMR (500 MHz, Chloroform-d) δ: 7.29 (s, 1H), 7.13 (s, 1H), 5.23 (s, 2H), 4.63 (t, 2H), 3.87 (s, 3H), 3.49 (s, 3H), 3.20 (t, 2H).
The solution of LiAlH4 (127 mg, 2 eq., 3.36 mmol) in THF (5 mL) was cooled to 0° C. and the solution of methyl 4-(methoxymethoxy)-2,3-dihydrobenzofuran-6-carboxylate (400 mg, 1 eq., 1.68 mmol) in THF (5 mL) was added dropwise. The cooling bath was removed and the mixture was stirred at 20° C. for 18 h. The mixture was cooled to 0° C. and water (130 μL) and 30% solution of K2CO3 (4×130 μL) were added dropwise. The mixture was filtered and the residue was washed by THF (5 mL). The organic layer was separated and concentrated to afford the crude title compound (340 mg, 1.48 mmol, 88.0%, 91.31% purity) as yellow oil, which was used in the next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ: 6.59 (s, 1H), 6.48 (s, 1H), 5.17 (s, 2H), 4.66-4.48 (m, 4H), 3.47 (s, 3H), 3.14 (t, 2H).
To the mixture of (7-(methoxymethoxy)-2,3-dihydrobenzofuran-5-yl)methanol (200 mg, 1 eq., 951 μmol) and 3,4-difluorophenol (124 mg, 1 eq., 951 μmol) in THF (40 mL) at 0° C. under Ar atmosphere were added tributylphosphane (385 mg, 0.48 mL, 2 eq., 1.90 mmol) and then (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone) (480 mg, 2 eq., 1.90 mmol). The mixture was stirred at 20° C. for 18 h. The solvent of the mixture was evaporated under reduced pressure. The residue was purified by reverse phase HPLC (water-acetonitrile) to afford the title compound (178 mg, 552 μmol, 58.1%). 1H NMR (500 MHz, Chloroform-d) δ: 7.04 (q, 1H), 6.83-6.71 (m, 1H), 6.64 (s, 2H), 6.54 (s, 1H), 5.19 (s, 2H), 4.92 (s, 2H), 4.60 (t, 2H), 3.49 (s, 3H), 3.17 (t, 2H).
Chlorotrimethylsilane (146 mg, 170 μL, 2 eq., 1.34 mmol) was added to MeOH (4 mL) at 0° C. dropwise. The mixture was stirred for 30 min and 5-((3,4-difluoro-phenoxy)methyl)-4-(methoxymethoxy)-2,3-dihydrobenzofuran (216 mg, 1 eq., 670 μmol) in MeOH (1 mL) was added followed by stirring at 20° C. for 18 h. The mixture was concentrated under reduced pressure to give crude title compound (178 mg, 623 μmol, 92.9%, 97.37% purity) as a beige solid. 1H NMR (500 MHz, DMSO-d6) δ: 9.50 (s, 1H), 7.34-7.27 (m, 1H), 7.14-7.01 (m, 1H), 6.83-6.73 (m, 1H), 6.34 (s, 1H), 6.28 (s, 1H), 4.92 (s, 2H), 4.47 (t, 2H), 2.99 (t, 2H).
To a solution of 5-((3,4-difluorophenoxy)methyl)-2,3-dihydrobenzofuran-4-ol (178 mg, 1 eq., 640 μmol) and triethylamine (84.2 mg, 116 μL, 1.3 eq., 832 μmol) in DCM (5 mL) trifluoromethanesulfonic anhydride (199 mg, 118 μL, 1.1 eq., 704 μmol) was added dropwise at 0° C. followed by stirring the mixture at 20° C. for 18 h. DCM (10 mL) was added to mixture and the solution was washed with NaHSO4 solution (2×5 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (238 mg, 0.52 mmol, 82%, 90% purity) as a brown oil, which was used in the next step without further purification. 1H NMR (500 MHz, Chloroform-d) δ: 7.06 (q, 1H), 6.84 (s, 1H), 6.80 (s, 1H), 6.79-6.72 (m, 1H), 6.66-6.60 (m, 1H), 4.96 (s, 2H), 4.68 (t, 2H), 3.34 (t, 2H).
Solution of potassium hydroxide (51.6 mg, 1.5 eq., 919 μmol) in water (0.6 mL) was added to a solution of methyl 2-methoxy-5-(4-(trifluoromethyl)phenoxy)-benzoate (0.200 g, 1 eq., 613 μmol) in methanol (5 mL). The mixture was stirred for 16 h at 25° C. and then concentrated under reduced pressure. The residue was dissolved in water (5 mL) and washed with EtOAc (2×2 mL). The aqueous mixture was acidified with NaHSO4 (5 mL, 15% in water). The resulting mixture was extracted with EtOAc (2×8 mL). The combined organic layers were dried under sodium sulfate and concentrated under reduced pressure to give the title compound (0.08 g, 0.26 mmol, 42%). LCMS: m/z 311.0 [M−H]−.
3-Methoxy-5-nitrophenol (0.5 g, 1 eq., 2.96 mmol), 4-trifluorophenylboronic acid (0.7 g, 1.5 eq., 4.43 mol), pyridine (1.2 g, 1.2 mL, 5 eq., 14.8 mol), diacetoxycopper (0.54 g, 1 eq., 2.96 mmol) and powdered molecular sieves 4 Å (1 g) were suspended in DCM (15 ml). The air was bubbled through the resulting solution for 30 min and the mixture was stirred at RT overnight. The mixture was filtered, the filtrate was washed with water (2×30 mL), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by method A to afford the title compound. LCMS: m/z 314.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 229 from the starting material indicated in the table.
To a mixture of 4-methoxy-3-nitrophenol (0.25 g, 1.47 mmol), 4-trifluoro-methyl-1-hydroxycyclohexane (0.20 ml, 1.47 mmol) and triphenylphosphine (465 mg, 1.77 mmol) in anhydrous THF (10 mL) under nitrogen was added DEAD (0.28 ml, 1.77 mmol) dropwise at RT and the mixture was left stirring for 24 h. The mixture was diluted with Et2O (30 ml) and washed with NaOH (2×10 ml), water (10 ml) and brine (10 ml). The organic phase was dried over sodium sulfate, filtered and concentrated. The crude residue was purified further with the purification method A to give 0.1 g of the title compound. LCMS: m/z 320.28 [M+H]+
The following intermediates were prepared according to the procedure described for Intermediate 240 from the starting material indicated in the table.
Triethyl phosphine (5.6 ml, 32.6 mmol) was added to 3-fluorobenzyl bromide (2.0 ml, 16.3 mmol) at RT under N2. The resulting mixture was heated at 150° C. for 2 h. The mixture was cooled and purified by flash chromatography to yield diethyl (3-fluorobenzyl)phosphonate. To the mixture of diethyl (3-fluorobenzyl)phosphonate (0.82 g, 3.3 mmol) in dry THF (10 ml) at 0-5° C. was added NaH (0.27 g, 11.0 mmol). After 30 min 4-methoxy-3-nitro benzaldehyde (0.5 g, 2.8 mmol) in dry THF (10 ml) was added dropwise to the mixture followed by stirred at RT for 3 h. The mixture was cooled, quenched with ice water (20 ml), made acidic with 2 M HCl and then extracted with ethyl acetate (2×10 ml). The combined organic layers were washed with water, dried, evaporated and then purified by flash chromatography to yield the title compound.
LCMS m/z 274.2 [M+H]+. 1H NMR (Chloroform-d, 400 MHz) δ: 8.0-8.0 (m, 1H), 7.6-7.7 (m, 1H), 7.2-7.4 (m, 4H), 6.9-7.1 (m, 3H), 3.99 (s, 3H).
A mixture of 3-(trifluoromethyl)benzaldehyde (0.20 ml, 1.4 mmol) and toluene sulfonhydrazide (0.27 g, 1.4 mmol) in 1,4-dioxane (10 ml) was heated at 60° C. for 90 min. To the obtained crude product of (E)-4-methyl-N′-(3-(trifluoromethyl)benzylide-ne)benzenesulfonohydrazide (0.4 g, 1.168 mmol) was added K2CO3 (0.24 g, 1.8 mmol) and 4-methoxy-3-nitrophenylboronic acid (0.23 g, 1.2 mmol). The mixture was heated under nitrogen atmosphere at 110° C. for 4 h followed by cooling to RT. The mixture was quenched with 2 M NaHCO3 (5 ml) and then extracted with ethyl acetate (2×10 ml). The combined organic layers were washed with water, dried, evaporated and purified by flash chromatography to yield the title compound. LCMS m/z 312.3 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ: 3.89-4.00 (m, 3H), 4.02 (s, 2H), 7.03 (d, 1H), 7.27-7.35 (m, 3H), 7.49-7.62 (m, 2H), 7.65-7.70 (m, 1H).
1-Methoxy-2-nitro-4-(4-(trifluoromethyl)benzyl)benzene was prepared using the procedure described for Intermediate 234 using 4-(trifluoromethyl)benzaldehyde as starting material. LCMS m/z 312.3 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ: 3.90-4.04 (m, 5H), 6.99-7.26 (m, 1H), 7.32-7.34 (m, 1H), 7.39-7.63 (m, 4H), 7.69 (d, 1H).
A mixture of 1-methoxy-3-nitro-5-(4-(trifluoromethyl)phenoxy)benzene (0.1 g, 1 eq., 0.32 mmol), zinc (0.21 g, 10 eq., 3.2 mmol), ammonium chloride (0.17 g, 10 eq., 3.2 mmol) in THF (5 ml), MeOH (2.5 ml) and water (2.5 ml) was stirred at RT for 4 h. The mixture was filtered through celite. The filtrate was washed with water (2>30 mL), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography to afford the title compound. LCMS m/z 284.1 [M]+
The following intermediates were prepared according to the procedure described for Intermediate 251 from the starting material indicated in the table.
A mixture of 1-methoxy-2-nitro-4-(3-(trifluoromethoxy)phenoxy)benzene 5 (0.050 g, 0.152 mol), zinc powder (0.050 g, 0.759 mmol), NH4Cl (0.041 g, 0.759 mmol), ethanol (1.5 ml) and water (0.5 ml) was stirred at 50° C. until the reaction was completed. The mixture was filtered through a pad of Celite. Celite layer was further washed with ethanol and the filtrate was evaporated to afford 0.040 g of the title compound. LCMS: m/z 299.8 [M+H]+.
The compound was prepared according to the procedure of Intermediate 257 starting from 4-(4-isopropoxyphenoxy)-1-methoxy-2-nitrobenzene (0.22 g, 0.725 mmol) using 4 eq. of zinc powder and 4 eq. of NH4Cl. Raw product was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.044 g. LCMS: m/z 273.9 [M+H]+.
A mixture of 1-methoxy-2-nitro-4-(4-(trifluoromethoxy)phenoxy)benzene (0.12 g, 0.364 mol), iron powder (0.061 g, 1.093 mmol), anhydrous CaCl2) (0.040 g, 0.364 mmol), ethanol (1.0 ml) and water (0.25 ml) was stirred at 60° C. until the reaction was completed. The mixture was filtered through a pad of Celite. Celite layer was washed with EtOAc. The filtrate was washed with water (2×), dried and evaporated to afford 0.090 g of the title compound. LCMS: m/z 299.7 [M]+
The following intermediates were prepared according to the procedure described for Intermediate 292 from the starting material indicated in the table.
The compound was prepared according to the procedure of Intermediate 292 starting from 2-nitro-4-(4-(trifluoromethyl)phenoxy)benzonitrile (0.36 g, 1.168 mmol). Raw product was purified by flash chromatography to afford the title compound. Yield: 0.21 g. LCMS: m/z 296.8 [M]+.
A mixture of 4-(cyclohexylmethoxy)-1-methoxy-2-nitrobenzene (0.26 g, 0.98 mol), zinc powder (0.32 g, 4.90 mmol, 5.0 eq.), NH4Cl (0.262 g, 4.90 mmol, 5.0 eq.), THF (3.0 ml), methanol (0.75 ml) and water (0.75 ml) was stirred at RT until the reaction was completed. The mixture was filtered through a pad of Celite. Celite layer was washed with EtOAc. The filtrate was washed with water (2×), dried and evaporated. Crude was purified by flash chromatography to afford 0.15 g of the title compound. LCMS: m/z 235.4 [M]+
The following intermediates were prepared according to the procedure described for Intermediate 298 from the starting material indicated in the table.
The compound was prepared using the procedure as described for Intermediate 298 starting from 4-(3-bromophenoxy)-1-methoxy-2-nitrobenzene (0.46 g, 1.419 mmol) using 7.5 eq. of zinc powder and 7.5 eq. of NH4Cl. Yield: 0.34 g. LCMS: m/z 294.2 [M]+.
The following intermediates were prepared according to the procedure described for Intermediate 306 from the starting material indicated in the table.
The compound was prepared according to the procedure of Intermediate 298 starting from 3-fluoro-2-(4-methoxy-3-nitrophenoxy)-5-(trifluoromethyl)pyridine (0.50 g, 1.505 mmol) using 10 eq. of zinc powder and 10 eq. of NH4Cl. Yield: 0.43 g. LCMS: m/z 303.5 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 312 from the starting material indicated in the table.
To a mixture of 3-nitro-5-(4-(trifluoromethyl)phenoxy)benzonitrile (0.22 g, 0.714 mmol) in 1,4-dioxane (3.5 ml) was added tin(II) chloride dihydrate (0.805 g, 3.57 mmol) dissolved in 37% aqueous HCl (1.0 ml). The mixture was stirred at RT until the reaction was completed. The mixture was made basic with 6 M NaOH solution. DCM was added and the mixture was filtered through a short plug of Celite. Celite was washed with DCM. Filtrate was dried and solvent evaporated to afford the title compound. Yield: 0.14 g. LCMS: m/z 279.3 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 315 from the starting material indicated in the table.
To a mixture of 4-methoxy-3-nitrophenol (0.169 g, 1.00 mmol), 3-(trifluoro-methoxy)phenylboronic acid (0.448 g, 2.18 mmol), anhydrous Cu(OAc)2 (0.182 g, 1.00 mmol) and powdered 4 Å molecular sieves (0.25 g) in dry DCM (7.5 ml) was added DIPEA (0.871 ml, 5.00 mmol). The mixture was stirred at RT until maximal conversion was obtained (48 h). The mixture was filtered through a plug of Celite and the Celite layer was washed with EtOAc. Filtrate was washed with 5% aqueous NH40H solution, dried and evaporated. Crude was purified by reverse phase flash chromatography to afford 0.050 g of the title compound. LCMS: m/z 330.2 [M+H]+.
To a mixture of 4-methoxy-3-nitrophenol (0.338 g, 2.00 mmol), 4-(trifluoro-methoxy)phenylboronic acid (0.618 g, 3.00 mmol), anhydrous Cu(OAc)2 (0.363 g, 2.00 mmol) and powdered 4 Å molecular sieves (0.25 g) in dry DCM (15 ml) was added pyridine (0.809 ml, 10.0 mmol). The mixture was stirred at RT until maximal conversion was obtained (24-48 h). The mixture was filtered through a plug of Celite and the Celite layer was washed with DCM. Filtrate was washed with 5% aqueous NH40H solution, dried and evaporated. Crude was purified by flash chromatography to afford 0.33 g of the title compound. LCMS: m/z 330.2 [M+H]+.
The following intermediates were prepared according to the procedure described for Intermediate 320 from the starting material indicated in the table.
To a cooled (0-5° C.) mixture of cyclohexylmethanol (0.285 g, 2.50 mmol), 4-methoxy-3-nitrophenol (0.423 g, 2.50 mmol) and triphenylphosphine (0.984 g, 3.75 mmol) in dry THF (17 ml) was added diisopropyl azodicarboxylate (0.738 ml, 3.75 mmol). The mixture was stirred over night at RT. THF was evaporated and the residue was dissolved in DCM. Organic phase was washed with water and brine, dried and evaporated. Crude product was purified by flash chromatography to afford 0.26 g of the title compound. LCMS: m/z 266.2 [M+H]+
The following intermediates were prepared according to the procedure described for Intermediate 333 from the starting material indicated in the table.
A mixture of 4-fluorobenzaldehyde (0.215 ml, 2.00 mmol), 4-methoxy-3-nitrophenol (0.338 g, 2.00 mmol) and potassium carbonate (0.553 g, 4.00 mmol) in dry DMA (4.0 ml) was stirred at 120° C. until the reaction was completed. Water was added to the cooled mixture and the mixture was extracted with EtOAc. Organic phase was washed with water, dried and evaporated to afford 0.49 g of the title compound. LCMS: m/z 274.1 [M+H]+.
4-(4-Methoxy-3-nitrophenoxy)benzaldehyde (0.49 g, 1.793 mmol) was dissolved in dry DCM (5.5 ml) and cooled to 0-5° C. Diethylaminosulfur trifluoride (0.521 ml, 3.95 mmol) was added in small portions and the mixture was stirred at RT for 24 h. The mixture was diluted with DCM and saturated NaHCO3 solution was added in small portions. Phases were separated and aqueous phase was extracted with DCM. Combined organic phases were washed with water and brine, dried and evaporated. Crude was purified by flash chromatography to afford 0.37 g of the title compound. LCMS: m/z 296.0 [M+H]+.
To a mixture of 3,4-difluorothiophenol (0.155 ml, 1.40 mmol), 4-methoxy-3-nitrophenylboronic acid (0.197 g, 1.00 mmol), copper(II) sulfate (8.0 mg, 0.05 mmol) and 1,10-phenanthroline (9.0 mg, 0.05 mmol) in ethanol (1.0 ml) (bubbled with oxygen before use) was added 40% aqueous tetrabutylammoniumhydroxide (1.0 ml, 3.82 mmol). The mixture was stirred over night at RT. Then mixture was diluted with EtOAc and filtered through a pad of Celite. Celite layer was further washed with EtOAc. Filtrate was evaporated and crude was purified by flash chromatography to afford 0.17 g of the title compound. 1H NMR (400 MHz, CDCl3): δ 7.88 (d, 1H), 7.56 (dd, 1H), 7.00-7.16 (m, 4H), 3.98 (s, 3H).
A mixture of 2-chloro-1-fluoro-4-(trifluoromethyl)benzene (0.397 g, 2.00 mmol), 4-methoxy-3-nitrophenol (0.372 g, 2.20 mmol) and potassium carbonate (0.608 g, 4.40 mmol) in dry DMF (4.0 ml) was stirred at 120° C. until the reaction was completed. Water was added to the cooled mixture followed by stirring at RT for 1 h. The formed precipitate was filtered, washed with water and dried under reduced pressure to afford 0.62 g of the title compound. LCMS: m/z 348.1 [M+H]+.
To a mixture of 2-chloro-1-(4-methoxy-3-nitrophenoxy)-4-(trifluoromethyl)-benzene (0.66 g, 1.898 mmol) and ammonium formate (1.197 g, 18.98 mmol) in dry methanol (35 ml) was added 10 wt-% palladium on carbon (0.253 g, 0.237 mmol). The mixture was vigorously stirred at RT until the reaction was completed. The mixture was filtered through a plug of Celite and the Celite layer was washed with methanol. Filtrate was evaporated and the residue was dissolved in EtOAc. Organic phase was washed with water, dried and evaporated to afford 0.52 g of the title compound. LCMS: m/z 284.5 [M+H]+.
A mixture of 4-methoxy-3-nitrophenol (0.677 g, 4.00 mmol, 1.0 eq.), 2-chloro-4-fluorobenzonitrile (0.622 g, 4.00 mmol, 1.0 eq.) and potassium carbonate (1.216 g, 8.80 mmol, 2.2 eq.) in dry DMF (5.5 ml) was stirred at 100-120° C. until reaction was completed. Cooled mixture was treated with water and the formed precipitate was filtered and dried to afford the title compound. Yield: 1.06 g. LCMS: m/z 304.5 [M+H]+. If the product did not precipitate from water, it was extracted with EtOAc. Organic phase was washed with water, dried and evaporated to afford the title compound which was used as such or purified by flash chromatography.
The following intermediates were prepared according to the procedure described for Intermediate 339 from the starting material indicated in the table.
A mixture of 4-(trifluoromethyl)phenol (0.40 g, 2.467 mmol), 4-fluoro-2-nitro-benzonitrile (0.40 g, 2.408 mmol) and potassium carbonate (0.666 g, 4.82 mmol) in dry DMA (5.0 ml) was stirred at 100° C. until the reaction was completed. Cooled mixture was diluted with water and extracted with EtOAc. Organic phase was dried and evaporated. Crude was purified by flash chromatography to afford the title compound. Yield: 0.40 g. 1H NMR (400 MHz, CDCl3) δ: 7.89 (d, 1H), 7.87 (d, 1H), 7.74-7.79 (m, 2H), 7.36 (dd, 1H), 7.20-7.25 (m, 2H).
A mixture of 4-(trifluoromethyl)phenol (0.324 g, 2.00 mmol), 3,5-dinitrobenzo-nitrile (0.463 g, 2.40 mmol) and potassium phosphate (0.849 g, 4.00 mmol) in dry DMA (3.0 ml) was stirred at 100° C. until the reaction was completed. Cooled mixture was diluted with water and extracted with EtOAc. Organic phase was dried and evaporated. Crude was purified by flash chromatography to afford the title compound. Yield: 0.42 g. LCMS: m/z 309.2 [M+H]+.
To a mixture of 4-(4-methoxy-3-nitrophenoxy)benzaldehyde (0.98 g, 3.59 mmol) in MeOH (15 ml) was added NaBH4 (0.204 g, 5.38 mmol) in small portions and stirred at RT until the reaction was completed. Solvent was evaporated and the residue was treated with water and EtOAc. Phases were separated and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with water and brine, dried and evaporated to afford the title compound. Yield 0.97 g. LCMS: m/z 258.3 [M−H2O+H]+.
To a cooled (−78° C.) solution of (4-(4-methoxy-3-nitrophenoxy)phenyl)methanol (0.48 g, 1.744 mmol) in dry DCM (5.0 ml) was added diethylaminosulfur trifluoride (DAST) (0.25 ml, 1.892 mmol). Cooling bath was removed and the mixture was allowed to warm to RT and stirred until the reaction was completed. The mixture was diluted with DCM (15 ml) and cooled to 0-5° C. Saturated NaHCO3 solution (5 ml) was added to adjust pH to 7-8. Phases were separated and aqueous phase was extracted with DCM. Combined organic phases were washed with water and brine, dried and evaporated. Crude product was purified by flash chromatography to afford the title compound. Yield: 0.26 g. 1H NMR (400 MHz, CDCl3) δ: 7.53 (d, 1H), 7.36-7.41 (m, 2H), 7.25 (dd, 1H), 7.08 (d, 1H), 6.98-7.03 (m, 2H), 5.35 (d, 2H), 3.96 (s, 3H).
A mixture of 5-amino-2,4-difluorophenol (0.218 g, 1.50 mmol) and potassium tert-butoxide (0.185 g, 1.65 mmol) in dry DMSO (3.0 ml) was stirred at RT for 1 h. 2-Chloro-5-(trifluoromethyl)pyridine (0.272 g, 1.50 mmol) and K2CO3 (0.104 g, 0.75 mmol) were added and stirring was continued at 120° C. until the reaction was completed. Cooled mixture was diluted with water and extracted with EtOAc. Organic phase was washed with 1 M NaOH and water, dried and evaporated. Crude product was purified by filtration through a short plug of silica gel eluting with EtOAc-heptane (4:1). Filtrate was evaporated and the residue dried under vacuum to afford the title compound. Yield: 0.25 g. LCMS: m/z 291.5 [M+H]+.
To a mixture of 2-methoxy-5-(4-(trifluoromethyl)phenoxy)aniline (0.085 g, 0.30 mmol), (2S,4R)-1-((benzyloxy)-carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (0.080 g, 0.30 mmol) in EtOAc (0.40 ml) and pyridine (0.20 ml) was added 1-propanephosphonic acid cyclic anhydride, 50 wt-% in EtOAc (0.30 ml, 0.509 mmol). The mixture was stirred at RT overnight. The reaction was quenched with 0.5% HCl-solution and diluted with water and EtOAc. Phases were separated and organic phase was washed with 0.5% HCl-solution, water and brine, dried and evaporated to afford the title compound. Yield: 0.111 g. LC-MS: m/z=531.3 [M+H]+. Crude product was used as such or purified by reverse phase flash chromatography to afford the pure compound.
The following intermediates were prepared according to the procedure described for Intermediate 352 from the starting material indicated in the table.
To a cooled (0-5° C.) mixture of tert-butyl 5-oxopyrrolidine-2-carboxylate (0.37 g, 2.00 mmol) in dry THF (5.0 ml) was added 60 wt-% NaH in oil (0.10 g, 2.50 mmol) followed by stirring at 0-5° C. for 30 min. 2-Methoxyacetyl chloride (0.26 g, 2.40 mmol) dissolved in dry THF (2.5 ml) was added and stirring continued at RT overnight. Solvent was evaporated and the residue treated with DCM and water. Phases were separated and the organic phase was washed with water and brine. Organic phase was dried and evaporated to afford the title compound. Yield: 0.51 g. LCMS: m/z 258.0 [M+H]+. Crude product was used as such or purified by reverse phase flash chromatography to afford the pure compound.
The following intermediates were prepared according to the procedure described for Intermediate 357 from the starting material indicated in the table.
To a cooled (0-5° C.) solution of tert-butyl L-prolinate (0.342 g, 2.00 mmol) and triethylamine (0.558 ml, 4.00 mmol) in dry DCM (10 ml) was added 2-methoxyacetyl chloride (0.239 g, 2.20 mmol). The mixture was stirred overnight at RT. The mixture was filtered and the filtrate was washed with saturated NH4Cl solution, saturated NaHCO3 solution, and brine, dried and evaporated to afford the title compound. Yield: 0.34 g. LCMS: m/z 244.2 [M+H]+.
A mixture of tert-butyl L-prolinate (0.342 g, 2.00 mmol), 2-bromoacetamide (0.331 g, 2.40 mmol) and potassium hydrogencarbonate (0.30 g, 3.00 mmol) in dry acetonitrile (10 ml) was stirred at 80° C. until the reaction was completed. Cooled mixture was filtered and the filtrate evaporated. Residue was treated with water and DCM. Phases were separated and the aqueous phase was extracted with DCM. Combined organic phases were dried and evaporated to afford the title compound. Yield: 0.34 g. LCMS: m/z 229.4 [M+H]+.
To a mixture of tert-butyl (S)-1-(2-methoxyacetyl)-5-oxopyrrolidine-2-carboxylate (0.77 g, 2.99 mmol) in dry DCM (15 ml) was added trifluoroacetic acid (2.50 ml, 32.4 mmol, 10.8 eq) followed by stirring overnight at RT. Solvent was evaporated and the residue was treated with toluene and evaporated again. This procedure was repeated and residue was dried under vacuum to afford the title compound. The crude product was either: (a) used in the next step as such or (b) extracted with DCM after basification with saturated Na2CO3 solution followed by drying and evaporating the organic phase. LCMS: m/z 201.9 [M+H]+
The following intermediates were prepared according to the procedure described for Intermediate 364 from the starting material indicated in the table.
A mixture of 5-bromo-2,3-dihydrobenzofuran-7-amine (0.158 g, 0.738 mmol), 2-[(E)-2-(4,4-difluorocyclohexyl)ethenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.243 g, 1.15 mmol), K3PO4 (0.313 g, 2.0 mmol) and SPhos Pd G2 (0.040 g, 0.075 mmol) in dioxane (1 ml) and water (1 ml) was heated under nitrogen atmosphere at 85° C. for 8 h. The mixture was extracted with ethyl acetate (2×4 ml). The combined organic layers were evaporated and then purified by normal phase chromatography to yield 0.144 g of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 1.34-1.46 (2H, m), 1.76-1.95 (4H, m), 1.97-2.09 (2H, m), 2.20-2.29 (1H, m), 3.08 (2H, t), 4.47 (2H, t), 4.57 (2H, s), 5.88-5.95 (1H, m), 6.21 (1H, d), 6.50 (1H, d), 6.53 (1H, br s). LCMS: m/z 280.7 [M+H]+
The following intermediate was prepared according to the procedure described for Intermediate 371 from the starting material indicated in the table.
Triethylamine (290 mg, 2.87 mmol, 1.2 eq.) was added to a suspension of the N-carbobenzyloxyglycine (1 eq.) in anhydrous CH2Cl2 (12 mL). The stirred mixture was cooled to 0° C. and 4-nitrophenyl chloroformate (578 mg, 2.87 mmol, 1.2 eq.) was added. After 10 min, DMAP (29.2 mg, 0.239 mmol, 0.1 eq.) was added and the mixture was stirred at 0° C. for 1 h. The mixture was further diluted with CH2Cl2 (20 mL) and washed with saturated NaHCO3 solution (10 mL), 0.1 M HCl solution (10 mL), brine (10 mL), and then dried (Na2SO4), filtered and evaporated in vacuum to give the crude product. The crude residue was purified further with reversed phase chromatography to obtain the title compound. LCMS: m/z 331.068 (M+H)+.
LiHMDS (896 μL, 0.896 mmol, 1.06 eq.) was added dropwise to a solution of 5-oxo-2-pyrrolidinecarboxylic acid tert-butyl ester (157 mg, 0.845 mmol, 1 eq.) in anhydrous THF (3 ml) at −78° C. under nitrogen. The mixture stirred at RT for 15 min followed by the addition of a solution of 4-nitrophenyl ((benzyloxy)carbonyl)glycinate in anhydrous THF (4 ml) at −78° C. The mixture was stirred for 1 h at this temperature. The mixture was diluted with ethyl acetate (20 ml) and washed with NH4Cl (10 ml), brine (10 ml) and then dried (Na2SO4), filtered and solvent evaporated in vacuum to give the crude product. The crude residue was purified further with reverse phase chromatography to obtain the title compound. LCMS: m/z 377.155 (M+H)+.
Trifluoroacetic acid was added dropwise to a solution of tert-butyl 1-(((benzyloxy)carbonyl)glycyl)-5-oxopyrrolidine-2-carboxylate (285 mg, 0.76 mmol, 1 eq.) in anhydrous DCM under nitrogen at 0° C. The mixture was stirred at 0° C. for 2 h. DCM and trifluoroacetic acid residue were removed in vacuum to give the crude product. The crude residue was purified further with reverse phase chromatography to obtain the title compound. LCMS: m/z 321.031 (M+H)+.
To a solution of 2-methoxy-5-(4-(trifluoromethyl)phenoxy)aniline (215 mg, 1 eq., 759 μmol) in anhydrous acetonitrile (5 mL) were added 5-oxopyrrolidine-2-carboxylic acid (98.0 mg, 1 eq., 759 μmol) and 1-methyl-1H-imidazole (312 mg, 5 eq., 3.80 mmol). The mixture was stirred at RT for 10 min and N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate (319 mg, 1.5 eq., 1.14 mmol) was added in a single portion. The resulting solution was stirred at RT overnight and the mixture was directly purified by method A to afford the title compound (0.194 g). 1H NMR (400 MHz, DMSO-d6) δ: 9.35 (s, 1H), 7.91 (d, 2H), 7.71 (d, 2H), 7.14 (d, 1H), 7.08 (d, 2H), 6.91 (dd, 1H), 4.38 (dd, 1H), 3.88 (s, 3H), 2.38-2.27 (m, 1H), 2.26-2.07 (m, 2H), 2.02-1.90 (m, 1H). LCMS: m/z 395.0 [M+H]+.
The following compounds were prepared according to the procedure described for Compound 1. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
1H NMR (400 MHz, DMSO-d6) δ: 9.68 (s, 1H), 7.91 (d, 1H), 7.71 (d, 2H), 7.17 (d, 1H), 7.09 (d, 2H), 6.95 (dd, 1H), 4.51 (dd, 1H), 4.37 (dd, 1H), 4.07 (dd, 1H), 2.70 (s, 3H). LCMS: m/z 431.0 [M + H]+
To a solution of 5-(3,4-difluorophenoxy)-2-(1,3,4-oxadiazol-2-yl)aniline (0.122 g, 1 eq., 422 μmol) in acetonitrile (3 mL) was added 1-methyl-5-oxopyrrolidine-2-carboxylic acid (72.5 mg, 1.2 eq., 506 μmol) and DIPEA (218 mg, 294 μL, 4 eq., 1.69 mmol). HATU (321 mg, 2 eq., 844 μmol) was then added and the mixture was stirred overnight at RT. N-(Chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate(V) (237 mg, 2 eq., 844 μmol) and 1-methyl-1H-imidazole (208 mg, 202 μL, 6 eq., 2.53 mmol) were added and the mixture was stirred overnight. The mixture was concentrated in vacuum, diluted with EtOAc (10 mL), washed with NaHSO4 (2 mL, 10%), K2CO3 (2 mL, 10%) and water (2 mL) followed by drying over Na2SO4. EtOAc was evaporated. The residue was purified by HPLC (2-10 min 0-55% of MeCN, flow rate: 30 mL/min) to afford the title compound (0.0242 g, 58.4 μmol, 13.8%, 100% purity). 1H NMR (600 MHz, DMSO-d6) δ: 10.89 (s, 1H), 9.38 (s, 1H), 8.01-7.89 (m, 2H), 7.57-7.50 (m, 1H), 7.45-7.38 (m, 1H), 7.04 (dd, J=8.0, 4.8 Hz, 1H), 6.96 (dd, J=8.8, 2.5 Hz, 1H), 4.26 (dd, J=9.1, 3.9 Hz, 1H), 2.70 (s, 3H), 2.38-2.21 (m, 3H), 2.01-1.93 (m, 1H). LCMS: m/z 415.0 [M+H]+.
The following compounds were prepared according to the procedure described for compound 224. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
2-Methoxy-5-(4-(trifluoromethyl)phenoxy)aniline (0.07 g, 1 eq., 0.25 mmol), (S)-1,3-dimethyl-2-oxoimidazolidine-4-carboxylic acid (39 mg, 1 eq., 0.25 mmol) and triethylamine hydrochloride (34 mg, 1 eq., 0.25 mmol) were dissolved in DMF (3 mL) followed by stirring for 10 min. Then 1-methyl-1H-imidazole (0.1 g, 99 μL, 5 eq., 1.2 mmol) was added followed by stirring for 10 min. N-(Chloro(dimethyl-amino)methylene)-N-methylmethanaminium hexafluorophosphate(V) (76 mg, 1.1 eq., 0.27 mmol) was then added in a single portion followed by stirring at 20° C. for 10 h. The mixture was filtered and the filtrate was purified by HPLC (Method A) to give the title compound (0.0314 g, 74.2 μmol, 30%, 100% purity). 1H NMR (400 MHz, DMSO-d6) δ: 9.57 (s, 1H), 7.88 (t, 1H), 7.71 (d, 2H), 7.15 (d, 1H), 7.08 (d, 2H), 7.00-6.88 (m, 1H), 4.40-4.26 (m, 1H), 3.88 (s, 3H), 3.54 (t, 1H), 3.26-3.16 (m, 1H), 2.64 (d, 6H). LCMS: m/z 424.2 [M+H]+.
The following compounds were prepared according to the procedure described for compound 226. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
2-Methoxy-5-(4-(trifluoromethyl)phenoxy)aniline (100 mg, 1 eq., 353 μmol), 4-acetoxy-1-methyl-5-oxopyrrolidine-3-carboxylic acid (92.3 mg, 1.3 eq., 459 μmol) and 1-methyl-1H-imidazole (174 mg, 169 μL, 6 eq., 2.12 mmol) were dissolved in acetonitrile (2 mL) followed by stirring the mixture at 22° C. for 10 min. Then N-(chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate(V) (198 mg, 2 eq., 706 μmol) was added. The mixture was stirred at 22° C. for 16 h. 4-Acetoxy-1-methyl-5-oxopyrrolidine-3-carboxylic acid (92.3 mg, 1.3 eq., 459 μmol) and N-(chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluoro-phosphate(V) (198 mg, 2 eq., 706 μmol) were added to the mixture followed by stirring at 22° C. for 16 h. The mixture was concentrated and ammonia (60.1 mg, 10 eq., 3.53 mmol) in methanol solution was added. The reaction mass was stirred at 22° C. for 16 h. The solution was purified by reverse phase HPLC (purification method A) to afford the title compound (5 mg, 0.01 mmol, 3%, 95% purity). 1H NMR (400 MHz, Methanol-d4) δ: 8.03-8.00 (m, 1H), 7.65-7.57 (m, 2H), 7.10-7.03 (m, 3H), 6.85 (m, 1H), 4.54 (dd, 1H), 3.93 (d, 3H), 3.77-3.67 (m, 1H), 3.58-3.47 (m, 2H), 3.31-3.25 (m, 1H), 2.88 (s, 3H). LCMS: m/z 425.1 [M+H]+.
To a solution of N-(2-methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)-5-oxo-pyrrolidine-2-carboxamide (0.047 g, 1 eq., 0.12 mmol) in DMF (2 mL) was added 5-oxopyrrolidine-2-carboxylic acid (15 mg, 1 eq., 0.12 mmol) and diisopropylethylamine (46 mg, 62 μL, 3 eq., 0.36 mmol). The mixture was stirred at RT for 15 minutes and HATU (68 mg, 1.5 eq., 0.18 mmol) was added in a single portion. The resulting solution was stirred at RT for 10 h. The mixture was concentrated in vacuum, diluted with ethylacetate (10 mL), washed with NaHSO4 (2 mL, 10%), K2CO3 (2 mL, 10%) and water (2 mL) followed by drying over Na2SO4. Ethyl acetate was evaporated and the residue was purified by method A to afford the title compound (0.0117 g). 1H NMR (400 MHz, DMSO-d6) δ: 9.78 (s, 1H), 7.87 (d, 1H), 7.77 (s, 1H), 7.69 (d, 2H), 7.14 (d, 1H), 7.06 (d, 2H), 6.90 (dd, 1H), 5.16-5.07 (m, 1H), 5.07-5.00 (m, 1H), 3.90 (s, 3H), 2.70-2.56 (m, 1H), 2.46-2.30 (m, 3H), 2.05-1.89 (m, 4H). LCMS: m/z 506.0 [M+H]+.
The following compounds were prepared according to the procedure described for Compound 229. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
To a mixture of 5-bromo-7-(3-(trifluoromethyl)phenoxy)-2,3-dihydrobenzo[b]-[1,4]dioxine (217.2 mg, 1 eq., 579.0 μmol), 1-methyl-5-oxopyrrolidine-2-carboxamide (123.5 mg, 1.5 eq., 868.5 μmol) and cesium carbonate (565.9 mg, 3 eq., 1.737 mmol) in toluene (4 mL) under argon Pd2(dba)3 (26.51 mg, 0.05 eq., 28.95 μmol) and 4,5-bis(di-phenylphosphino)-9,9-dimethylxanthene (50.25 mg, 0.15 eq., 86.85 μmol) were added and the mixture was heated at 110° C. for 18 h. After cooling to RT the mixture was concentrated and the residue was purified by method A to afford the title compound (0.0286 g). 1H NMR (600 MHz, DMSO-d6) δ: 9.68 (s, 1H), 7.59-7.54 (m, 1H), 7.42 (d, 1H), 7.39 (d, 1H), 7.25-7.19 (m, 2H), 6.47 (d, 1H), 4.44 (dd, 1H), 4.35-4.27 (m, 4H), 2.61 (s, 3H), 2.27-2.12 (m, 3H), 1.89-1.82 (m, 1H). LCMS: m/z 437.0 [M+H]+.
The following compounds were prepared according to the procedure described for Compound 233. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
Chlorotrimethylsilane (210 mg, 245 μL, 5 eq., 1.93 mmol) was added slowly to methanol (5 mL) at 0° C. and the mixture was stirred at 0° C. for 30 min. To the obtained solution tert-butyl (3-fluorophenyl)(4-methoxy-3-(5-oxopyrrolidine-2-carboxamido)-benzyl)carbamate (300 mg, 58.89%, 1 eq., 386 μmol) was added and the mixture was stirred at RT for 18 h. The mixture was treated with aqueous NaHCO3 solution (10 mL) and extracted with ethyl acetate (2×20 mL). Combined organic phases were washed with brine (2×15 mL), dried over sodium sulfate, filtered, concentrated and the residue was purified by reverse phase HPLC (water-acetonitrile) to afford the title compound (0.0201 g). 1H NMR (400 MHz, DMSO-d6) δ: 9.17 (s, 1H), 8.04-7.90 (m, 2H), 7.12-6.96 (m, 3H), 6.58-6.49 (m, 1H), 6.39 (dd, 1H), 6.32-6.18 (m, 2H), 4.34 (dd, 1H), 4.16 (d, 2H), 3.82 (s, 3H), 2.38-2.28 (m, 1H), 2.28-2.02 (m, 2H), 2.03-1.85 (m, 1H). LCMS: m/z 358.2 [M+H]+.
N-(5-hydroxy-2-methoxyphenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.0667 g, 1 eq., 252 μmol), triphenylphosphine (86.1 mg, 1.3 eq., 328 μmol) and DEAD (54.9 mg, 49.5 μL, 1.25 eq., 315 μmol) were dissolved in THF (5.5 mL). The mixture was stirred at RT for 30 min. 4,4-Difluorocyclohexan-1-ol (48.1 mg, 1.4 eq., 353 μmol) was added to the mixture at RT and stirred for 58 h. The mixture was purified by column chromatography to give the title compound (0.0032 g, 7.9 μmol, 3.1%, 95% purity). Purification method C. 1H NMR (400 MHz, Methanol-d4) δ: 7.75 (d, 1H), 6.97 (d, 1H), 6.77 (dd, 1H), 4.48-4.40 (m, 2H), 3.87 (s, 3H), 2.85 (s, 3H), 2.59-2.47 (m, 1H), 2.47-2.34 (m, 2H), 2.19-2.04 (m, 3H), 1.99-1.84 (m, 6H). LCMS: m/z 383.2 [M+H]+.
7-Bromo-5-((3,4-difluorobenzyl)oxy)-2,3-dihydrobenzofuran (0.100 g, 1 eq., 293 μmol), 1-methyl-5-oxopyrrolidine-2-carboxamide (50.0 mg, 1.2 eq., 352 μmol), cesium carbonate (95.5 mg, 1 eq., 293 μmol), copper (I) iodide (16.7 mg, 0.3 eq., 87.9 μmol) and N1,N2-dimethylcyclohexane-1,2-diamine (25.0 mg, 0.6 eq., 176 μmol) were mixed in N,N-dimethylformamide (2 mL). The mixture was heated at 100° C. under argon atmosphere for 12 h. Then N,N-dimethylformamide was evaporated and the residue was diluted with EtOAc (10 mL), washed with water (2×2 mL), dried over Na2SO4 and concentrated in vacuum. A sample of reaction mixture was analyzed by LCMS. Residue was purified by method A to afford the title compound (0.0035 g). 1H NMR (400 MHz, Acetonitrile-d3) δ: 8.03 (s, 1H), 7.59 (d, 1H), 7.46-7.36 (m, 1H), 7.36-7.24 (m, 2H), 6.74 (d, 1H), 5.01 (s, 2H), 4.61 (t, 2H), 4.23 (dd, 1H), 3.24 (t, 2H), 2.78 (s, 3H), 2.45-2.24 (m, 3H). LCMS: m/z 403.0 [M+H]+.
The following compounds were prepared according to the procedure described for Compound 248. The compound number, structure, starting materials, purification method and characterization data are indicated in the table.
N-(2-Methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)-5-oxotetrahydropyrrolo-[2,1-b]thiazole-7a(5H)-carboxamide (100 mg, 1 eq., 221 μmol) was dissolved in acetic acid (3 mL) and potassium permanganate (55.9 mg, eq., 354 μmol) was added at RT. The mixture was stirred at RT for 24 h. The mixture was poured into sodium hydrocarbonate saturated solution (30 mL) followed by extraction with ethyl acetate (3×30 mL). Combined organic phases were washed with brine (2×30 mL), dried over sodium sulfate, filtered, concentrated and the residue was purified by purification method A to afford the title compound (0.0079 g). 1H NMR (400 MHz, Acetonitrile-d3) δ: 8.77 (s, 1H), 7.99 (d, 1H), 7.70 (d, 2H), 7.15-7.05 (m, 3H), 6.96 (dd, 1H), 4.52-4.38 (m, 1H), 3.95 (s, 3H), 3.73-3.64 (m, 1H), 3.45-3.26 (m, 2H), 2.87-2.66 (m, 3H), 2.57-2.42 (m, 1H). LCMS: m/z 485.2 [M+H]+.
To a solution of 5-oxopyrrolidine-2-carboxylic acid (51.1 mg, 0.40 mmol), 3-methoxy-5-(4-(trifluoromethyl)phenoxy)aniline (112 mg, 0.40 mmol), HATU (226 mg, 0.60 mmol) and dry DMF (2 ml) was added DIPEA (0.34 ml, 2.0 mmol). The mixture was stirred at RT overnight. The reaction mixture was quenched with water (10 ml) followed by extraction with ethyl acetate (2×10 ml). The combined organic layers were washed with water, dried, evaporated and then purified by reverse phase chromatography to yield 0.074 g the title compound. 1H NMR (600 MHz, DMSO-d6) δ: 1.93-2.00 (m, 1H), 2.08-2.22 (m, 2H), 2.28-2.36 (m, 1H), 3.75 (s, 3H), 4.14 (dd, 1H), 6.48 (t, 1H), 6.97 (t, 1H), 7.15-7.21 (m, 3H), 7.76 (d, 2H), 7.86 (s, 1H), 10.14 (s, 1H). LCMS: m/z 395.2 [M+H]+
The following compounds were prepared according to the procedure described for Compound 253. The compound number, structure, starting materials, purification method and characterization data are indicated in the table.
1H NMR (600 MHz, DMSO-d6) δ: 1.85- 1.98 (m, 1H), 2.17-2.33 (m, 3H), 2.65 (s, 3H), 3.70-3.75 (m, 3H), 4.08-4.19 (m, 1H), 6.48 (s, 1H), 6.94 (t, 1H), 7.15-7.20 (m, 3H), 7.75 (d, 2H), 10.30 (s, 1H). LCMS: m/z 409.1 [M + H]+
To a mixture of 2-methoxy-5-(4-(trifluoromethoxy)phenoxy)aniline (0.060 g, 0.20 mmol), (2R)-1-methyl-5-oxopyrrolidine-2-carboxylic acid (0.029 g, 0.20 mmol) and HATU (0.114 g, 0.30 mmol) in dry DMF (1.0 ml) was added DIPEA (0.174 ml, 1.00 mmol). The mixture was stirred overnight at RT. The mixture was diluted with EtOAc and washed with water and brine. Organic phase was dried and evaporated. The crude product was purified by reverse phase flash chromatography to afford 0.056 g of the of the title compound. 1H NMR (400 MHz, CDCl3) δ: 8.17 (d, 1H), 8.07 (s, 1H), 7.11-7.18 (m, 2H), 6.91-6.98 (m, 2H), 6.87 (d, 1H), 6.77 (dd, 1H), 4.07-4.14 (m, 1H), 3.90 (s, 3H), 2.94 (s, 3H), 2.37-2.63 (m, 3H), 2.10-2.20 (m, 1H). LCMS: m/z 425.0 [M+H]+
The following compounds were prepared according to the procedure described for Compound 290. The compound number, structure, starting materials, purification method and characterization data are indicated in the table.
1H NMR (400 MHz, CDCl3) δ: 8.19 (d, 1H), 8.08 (s, 1H), 7.29 (t, 1H), 6.85-6.92 (m, 3H), 6.77-6.82 (m, 2H), 4.08-4.14 (m, 1H), 3.91 (s, 3H), 2.94 (s, 3H), 2.37-2.63 (m, 3H), 2.11-2.20 (m, 1H). LCMS: m/z 425.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.18 (d, 1H), 8.07 (s, 1H), 7.40-7.48 (m, 2H), 6.95-7.05 (m, 2H), 6.89 (d, 1H), 6.80 (dd, 1H), 6.61 (t, 1H), 4.07-4.14 (m, 1H), 3.91 (s, 3H), 2.94 (s, 3H), 2.37-2.63 (m, 3H), 2.11-2.20 (m, 1H). LCMS: m/z 391.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.13 (d, 1H), 8.05 (s, 1H), 6.98 (dd, 1H), 6.85 (d, 1H), 6.74 (dd, 1H), 6.66 (dd, 1H), 6.39-6.46 (m, 1H), 4.07-4.13 (m, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 2.94 (s, 3H), 2.37-2.63 (m, 3H), 2.10-2.20 (m, 1H). LCMS: m/z 389.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.05 (d, 1H), 8.03 (s, 1H), 6.80 (d, 1H), 6.61 (dd, 1H), 4.11 (dd, 1H), 3.84 (s, 3H), 3.72 (d, 2H), 2.93 (s, 3H), 2.54- 2.66 (m, 1H), 2.36-2.54 (m, 2H), 2.11- 2.21 (m, 1H), 1.81-1.91 (m, 2H), 1.63- 1.81 (m, 4H), 1.12-1.36 (m, 3H), 0.96- 1.10 (m, 2H). LCMS: m/z 361.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.12 (d, 1H), 8.05 (s, 1H), 6.81-6.95 (m, 2H), 6.67-6.79 (m, 3H), 4.06-4.14 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 2.93 (s, 3H), 2.36-2.64 (m, 3H), 2.10-2.21 (m, 1H). LCMS: m/z 389.0 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.07 (d, 1H), 8.03 (s, 1H), 6.79 (d, 1H), 6.64 (dd, 1H), 4.06-4.22 (m, 2H), 3.84 (s, 3H), 2.93 (s, 3H), 2.36-2.67 (m, 3H), 2.11-2.23 (m, 1H), 1.78-1.91 (m, 2H), 1.58-1.70 (m, 2H), 1.43-1.57 (m, 2H), 1.18-1.32 (m, 2H), 0.96 (s, 3H), 0.93 (s, 3H). LCMS: m/z 375.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.51 (d, 1H), 8.02 (s, 1H), 7.21 (dd, 1H), 6.94-7.10 (m, 3H), 6.90 (d, 1H), 4.08- 4.14 (m, 1H), 3.92 (s, 3H), 2.94 (s, 3H), 2.37-2.65 (m, 3H), 2.11-2.20 (m, 1H). LCMS: m/z 393.3 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.51 (d, 1H), 8.30 (s, 1H), 7.20 (dd, 1H), 6.92-7.10 (m, 1H), 6.89 (d, 1H), 6.36 (s, 1H), 4.30 (ddd, 1H), 3.92 (s, 3H), 2.57-2.70 (m, 1H), 2.45-2.57 (m, 1H), 2.22-2.45 (m, 2H). LCMS: m/z 379.2 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.16 (d, 1H), 8.06 (s, 1H), 7.13-7.18 (m, 2H), 7.04-7.07 (m, 1H), 6.89-6.92 (m, 1H), 6.87 (d, 1H), 6.77 (dd, 1H), 4.10 (dd, 1H), 3.91 (s, 3H), 2.94 (s, 3H), 2.54-2.62 (m, 1H), 2.38-2.52 (m, 2H), 2.12-2.19 (m, 1H). LCMS: m/z 419.2 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.34 (s, 1H), 8.16 (d, 1H), 7.11-7.16 (m, 2H), 6.91-6.96 (m, 2H), 6.86 (d, 1H), 6.76 (dd, 1H), 6.39 (s, 1H), 4.29 (ddd, 1H), 3.89 (s, 3H), 2.58-2.67 (m, 1H), 2.46-2.54 (m, 1H), 2.34-2.42 (m, 1H), 2.24-2.32 (m, 1H). LCMS: m/z 411.3 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.30 (s, 1H), 8.11 (d, 1H), 6.87-6.93 (m, 2H), 6.78-6.87 (m, 3H), 6.69 (dd, 1H), 6.22 (s, 1H), 4.46 (sept, 1H), 4.28 (ddd, 1H), 3.87 (s, 3H), 2.56-2.68 (m, 1H), 2.44-2.56 (m, 1H), 2.33-2.44 (m, 1H), 2.22-2.33 (m, 1H), 1.32 (d, 6H). LCMS: m/z 385.2 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.07 (d, 1H), 8.04 (s, 1H), 6.81 (d, 1H), 6.62 (dd, 1H), 4.09-4.13 (m, 1H), 3.97 (d, 2H), 3.85 (s, 3H), 2.93 (s, 3H), 2.65-2.75 (m, 2H), 2.54-2.63 (m, 2H), 2.38-2.53 (m, 4H), 2.12-2.19 (m, 1H). LCMS: m/z 369.3 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.23 (s, 1H), 7.78-7.85 (m, 1H), 7.48-7.55 (m, 1H), 6.99-7.12 (m, 4H), 6.94-6.99 (m, 1H), 4.16 (dd, 1H), 2.84 (s, 3H), 2.44-2.60 (m, 2H), 2.24-2.39 (m, 1H), 2.09-2.22 (m, 1H). LCMS: m/z 397.5 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.14 (d, 1H), 8.05 (s, 1H), 7.21-7.28 (m, 2H), 6.82-6.92 (m, 3H), 6.75 (dd, 1H), 4.09 (dd, 1H), 3.89 (s, 3H), 2.93 (s, 3H), 2.36-2.65 (m, 3H), 2.09-2.22 (m, 1H). LCMS: m/z 375.0 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.17 (d, 1H), 8.07 (s, 1H), 7.22-7.34 (m, 1H), 6.88 (d, 1H), 6.78 (dd, 1H), 6.63- 6.75 (m, 2H), 4.04-4.16 (m, 1H), 3.91 (s, 3H), 2.94 (s, 3H), 2.34-2.65 (m, 3H), 2.08-2.22 (m, 1H). LCMS: m/z 393.1 [M + H]+
1H NMR (400 MHz, d6-DMSO) δ: 10.6 (s, 1H), 7.94 (s, 1H), 7.75-7.86 (m, 2H), 7.53-7.61 (m, 1H), 7.39-7.47 (m, 1H), 7.23-7.34 (m, 2H), 4.15-4.25 (m, 1H), 2.67 (s, 3H), 2.16-2.38 (m, 3H), 1.85-1.99 (m, 1H). LCMS: m/z 404.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.14 (d, 1H), 8.05 (s, 1H), 7.21-7.28 (m, 2H), 6.86-6.92 (m, 2H), 6.86 (d, 1H), 6.75 (dd, 1H), 4.09 (dd, 1H), 3.89 (s, 3H), 2.93 (s, 3H), 2.36-2.63 (m, 3H), 2.09-2.19 (m, 1H). LCMS: m/z 375.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.14 (d, 1H), 8.05 (s, 1H), 7.21-7.28 (m, 2H), 6.86-6.92 (m, 2H), 6.86 (d, 1H), 6.75 (dd, 1H), 4.09 (dd, 1H), 3.89 (s, 3H), 2.93 (s, 3H), 2.36-2.63 (m, 3H), 2.09-2.19 (m, 1H). LCMS: m/z 375.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.20 (d, 1H), 8.11 (s, 1H), 7.57 (d, 1H), 6.98 (d, 1H), 6.93 (d, 1H), 6.90 (dd, 1H), 6.82 (dd, 1H), 4.12 (dd, 1H), 3.94 (s, 3H), 2.94 (s, 3H), 2.37-2.65 (m, 3H), 2.10-2.21 (m, 1H). LCMS: m/z 400.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.20 (d, 1H), 8.11 (s, 1H), 7.57 (d, 1H), 6.98 (d, 1H), 6.93 (d, 1H), 6.90 (dd, 1H), 6.82 (dd, 1H), 4.12 (dd, 1H), 3.94 (s, 3H), 2.94 (s, 3H), 2.37-2.65 (m, 3H), 2.10-2.21 (m, 1H). LCMS: m/z 400.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.08 (s, 1H), 8.19 (d, 1H), 7.46-7.60 (m, 2H), 6.93-7.06 (m, 2H), 6.87 (d, 1H), 6.78 (dd, 1H), 4.34 (dd, 1H), 3.92 (s, 3H), 3.55-3.66 (m, 1H), 3.38-3.49 (m, 1H), 2.94 (s, 3H), 2.38-2.49 (m, 1H), 2.08-2.22 (m, 1H), 1.94-2.07 (m, 2H). LCMS: m/z 459.6 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.17 (d, 1H), 8.07 (s, 1H), 7.24-7.32 (m, 1H), 6.88 (d, 1H), 6.78 (dd, 1H), 6.67- 6.75 (m, 2H), 4.10 (dd, 1H), 3.91 (s, 3H), 2.94 (s, 3H), 2.36-2.64 (m, 3H), 2.10-2.21 (m, 1H). LCMS: m/z 393.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.18 (d, 1H), 8.07 (s, 1H), 7.38-7.48 (m, 2H), 6.94-7.04 (m, 2H), 6.88 (d, 1H), 6.79 (dd, 1H), 6.61 (t, 1H), 4.10 (dd, 1H), 3.91 (s, 3H), 2.93 (s, 3H), 2.36- 2.64 (m, 3H), 2.09-2.20 (m, 1H). LCMS: m/z 391.3 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.11 (d, 1H), 8.01 (s, 1H), 7.26 (d, 1H), 7.22 (d, 1H), 7.05 (d, 1H), 6.97 (dd, 1H), 6.79 (d, 1H), 6.69 (dd, 1H), 6.39 (d, 1H), 4.03-4.10 (m, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 2.92 (s, 3H), 2.33- 2.64 (m, 3H), 2.07-2.19 (m, 1H). LCMS: m/z 394.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.09 (d, 1H), 8.03 (s, 1H), 6.84-6.89 (m, 1H), 6.81 (d, 1H), 6.75 /dd, 1H), 6.70 (d, 1H), 6.68 (dd, 1H), 4.57 (t, 2H), 4.09 (dd, 1H), 3.87 (s, 3H), 3.18 (t, 2H), 2.93 (s, 3H), 2.35-2.64 (m, 3H), 2.10-2.20 (m, 1H). LCMS: m/z 393.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.16 (d, 1H), 8.07 (s, 1H), 7.21 (t, 1H), 7.01 (d, 1H), 6.82-6.95 (m, 3H), 6.78 (dd, 1H), 4.06-4.15 (m, 1H), 3.91 (s, 3H), 2.94 (s, 3H), 2.35-2.66 (m, 3H), 2.09- 2.22 (m, 1H). LCMS: m/z 375.1 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.18 (d, 1H), 8.09 (s, 1H), 7.50 (d, 1H), 6.91 (d, 1H), 6.74-6.84 (m, 3H), 4.11 (dd, 1H), 3.92 (s, 3H), 2.94 (s, 3H), 2.48 (s, 3H), 2.37-2.65 (m, 3H), 2.10- 2.20 (m, 1H). LCMS: m/z 380.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.33 (s, 1H), 8.22 (d, 1H), 7.49-7.58 (m, 2H), 6.95-7.03 (m, 2H), 6.90 (d, 1H), 6.79 (dd, 1H), 4.36-4.44 (m, 1H), 3.92 (s, 3H), 3.80-3.89 (m, 1H), 3.49-3.61 (m, 1H), 3.31 (s, 3H), 3.25-3.36 (m, 1H), 2.53-2.67 (m, 1H), 2.29-2.47 (m, 2H), 2.14-2.27 (m, 1H). LCMS: m/z 453.6 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.18 (d, 1H), 8.07 (s, 1H), 7.38-7.48 (m, 2H), 6.94-7.04 (m, 2H), 6.88 (d, 1H), 6.79 (dd, 1H), 6.61 (t, 1H), 4.10 (dd, 1H), 3.91 (s, 3H), 2.93 (s, 3H), 2.36- 2.64 (m, 3H), 2.09-2.20 (m, 1H). LCMS: m/z 391.3 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.24 (br. s, 1H), 8.17 (d, 1H), 7.54 (m, 2H), 7.00 (m, 2H), 6.90 (d, 1H), 6.81 (dd, 1H), 4.04 (dd, 1H), 3.91 (s, 3H), 3.04 (s, 3H), 2.57 (dt, 1H), 2.44 (m, 1H), 2.25 (m, 1H), 2.15-2.06 (m, 1H), 1.86- 1.80 (m, 2H). LCMS: m/z 423.5 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.22 (br. s, 1H), 8.13 (d, 1H), 7.07 (m, 1H), 6.86 (d, 1H), 6.78-6.73 (m, 2H), 6.70- 6.66 (m, 1H), 4.04 (dd, 1H), 3.89 (s, 3H), 3.04 (s, 3H), 2.56 (dt, 1H), 2.44 (m, 1H), 2.25 (m, 1H), 2.10 (m, 1H), 1.88-1.80 (m, 2H). LCMS: m/z 391.2 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.21 (d, 1H), 7.87 (br. s, 1H), 7.53 (m, 2H), 6.98 (m, 2H), 6.88 (d, 1H), 6.78 (dd, 1H), 3.92 (s, 3H), 3.43-3.34 (m, 2H), 2.97 (s, 3H), 2.80 (m, 1H), 2.70-2.63 (m, 2H), 2.17 (m, 1H), 2.06 (m, 1H). LCMS: m/z 423.3 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 2.24- 2.36 (m, 2H), 2.91 (s, 3H), 3.14 (ddd, 1 H), 3.42-3.48 (m, 1H), 3.52 (ddd, 1H), 3.59 (dd, 1H), 3.68 (dd, 1H), 3.93 (s, 3H), 6.78 (dd, 1H), 6.89 (d, 1H), 6.98 (m, 1H), 7.00 (m, 1H), 7.53 (m, 1H), 7.54 (m, 1H), 7.96 (brs, 1H), 8.17 (d, 1H). LCMS: m/z 459.168 (M + H)+
To a mixture of 2-fluoro-5-(4-(trifluoromethoxy)phenoxy)aniline (0.069 g, 0.24 mmol), 1-methyl-5-oxopyrrolidine-2-carboxylic acid (0.034 g, 0.24 mmol) and 1-methylimidazole (0.071 ml, 0.89 mmol) in dry acetonitrile (1.0 ml) was added N,N,N′,N′-tetramethylchloroformamidinium-hexafluorophosphate (0.081 g, 0.288 mmol). The mixture was stirred overnight at RT. The mixture was diluted with EtOAc and washed with water and brine. Organic phase was dried and evaporated. Crude product was purified by reverse phase flash chromatography to afford 0.028 g of the title compound. 1H NMR (400 MHz, CDCl3) δ: 8.05 (dd, 1H), 7.81 (s, 1H), 7.14-7.23 (m, 2H), 7.05-7.14 (m, 1H), 6.92-7.03 (m, 2H), 6.71-6.80 (m, 1H), 4.10-4.19 (m, 1H), 2.93 (s, 3H), 2.37-2.64 (m, 3H), 2.10-2.21 (m, 1H). LCMS: m/z 413.0 [M+H]+.
The following compounds were prepared according to the procedure described for Compound 328. The compound number, structure, starting materials and characterization data are indicated in the table.
1H NMR (400 MHz, CDCl3) δ: 8.14 (d, 1H), 8.00 (s, 1H), 7.36 (d, 1H), 7.17-7.24 (m, 2H), 6.99-7.06 (m, 2H), 6.75 (dd, 1H), 4.10-4.16 (m, 1H), 2.97 (s, 3H), 2.39-2.65 (m, 3H), 2.12-2.21 (m, 1H). LCMS: m/z 429.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 12.5 (s, 1H), 8.50 (d, 1H), 7.58-7.74 (m, 3H), 7.44 (br s, 1H), 7.10-7.19 (m, 2H), 6.77 (dd, 1H), 6.66 (br s, 1H), 4.11 (dd, 1H), 2.94 (s, 3H), 2.34- 2.66 (m, 3H), 2.09-2.21 (m, 1H). LCMS: m/z 422.1 [M + H]+
To a mixture of 2-methoxy-5-((4-(trifluoromethyl)pyridin-2-yl)oxy)aniline (0.071 g, 0.25 mmol), 1-(2-methoxyacetyl)-5-oxopyrrolidine-2-carboxylic acid (0.053 g, 0.25 mmol) in EtOAc (0.30 ml) and pyridine (0.15 ml) was added 1-propanephosphonic acid cyclic anhydride, 50 wt-% in EtOAc (0.25 ml, 0.424 mmol). The mixture was stirred at RT overnight. Reaction was quenched with 0.5% HCl-solution and diluted with water and EtOAc. Phases were separated and organic phase was washed with 0.5% HCl-solution, water and brine, dried and evaporated. Crude product was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.046 g. 1H NMR (400 MHz, CDCl3) δ: 8.45 (s, 1H), 8.30 (d, 1H), 8.20 (s, 1H), 7.04-7.22 (m, 2H), 6.82-7.00 (m, 2H), 4.88 (d, 1H), 4.52-4.74 (m, 2H), 3.93 (s, 3H), 3.47 (s, 3H), 2.84-3.03 (m, 1H), 2.47-2.64 (m, 1H), 2.22-2.47 (m, 2H). LCMS: m/z 468.5 [M+H]+
The following compounds were prepared according to the procedure described for Compound 331. The compound number, structure, starting materials and characterization data are indicated in the table.
1H NMR (400 MHz, CDCl3) δ: 9.05 (s, 1H), 8.21 (d, 1H), 7.50-7.57 (m, 2H), 6.96-7.02 (m, 2H), 6.88 (d, 1H), 6.80 (dd, 1H), 5.33 (d, 1H), 4.29- 4.36 (m, 1H), 3.89 (s, 3H), 3.85-3.92 (m, 1H), 3.53 (dd, 1H), 2.83 (s, 3H). LCMS: m/z 410.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.44 (s, 1H), 8.14 (d, 1H), 7.49-7.56 (m, 2H), 6.94-7.00 (m, 2H), 6.88 (d, 1H), 6.79 (dd, 1H), 4.86 (dd, 1H), 4.57- 4.69 (m, 2H), 3.92 (s, 3H), 3.47 (s, 3H), 2.88-3.01 (m, 1H), 2.49-2.59 (m, 1H), 2.25-2.45 (m, 2H). LCMS: m/z 467.5 [M + H]+
1H NMR (600 MHz, d6-DMSO) δ: 9.80 (s, 1H), 8.38 (dd, 1H), 8.34-8.37 (m, 1H), 7.93 (d, 1H), 7.13 (d, 1H), 7.00 (dd, 1H), 5.09 (dd, 1H), 4.48 (q, 2H), 3.91 (s, 3H), 3.29 (s, 3H), 2.54- 2.62 (m, 1H), 2.45-2.52 (m, 1H), 2.31-2.40 (m, 1H), 1.96-2.02 (m, 1H). LCMS: m/z 486.5 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.20 (d, 1H), 7.91 (s, 1H), 7.49-7.57 (m, 2H), 6.95-7.03 (m, 2H), 6.89 (d, 1H), 6.79 (dd, 1H), 6.14 (s, 1H), 3.92 (s, 3H), 3.60-3.76 (m, 2H), 3.38 (quint., 1H), 2.75 (dd, 1H), 2.61 (dd, 1H). LC-MS: m/z 395.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.26 (s, 1H), 8.16 (d, 1H), 7.48-7.55 (m, 2H), 6.93-7.00 (m, 2H), 6.85 (d, 1H), 6.74 (dd, 1H), 4.78 (dd, 1H), 4.07- 4.18 (m, 2H), 3.91 (s, 3H), 3.54-3.63 (m, 1H), 3.48 (s, 3H), 3.42-3.52 (m, 1H), 2.40-2.51 (m, 1H), 2.09-2.24 (m, 1H), 1.83-2.09 (m, 1H). LCMS: m/z 453.6 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.46 (s, 1H), 8.23 (d, 1H), 7.49-7.57 (m, 2H), 6.95-7.03 (m, 2H), 6.89 (d, 1H), 6.77 (dd, 1H), 6.58 (bs, 1H), 5.81 (bs, 1H), 3.90 (s, 3H), 3.54 (d, 1H), 3.33-3.43 (m, 2H), 3.19 (d, 1H), 2.49-2.59 (m, 1H), 2.26-2.39 (m, 1H), 1.85-2.07 (m, 3H). LCMS: m/z 438.8 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.59 (s, 1H), 8.16 (d, 1H), 7.28 (t, 1H), 6.89 (d, 1H), 6.79 (dd, 1H), 6.66- 6.76 (m, 2H), 5.15 (s, 1H), 4.13 (dd, 1H), 3.91 (s, 3H), 3.86 (t, 1H), 3.46 (t, 1H), 2.92 (s, 3H). LCMS: m/z 394.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.62 (s, 1H), 8.28-8.31 (m, 1H), 8.15-8.19 (m, 1H), 7.67 (dd, 1H), 6.91-6.97 (m, 2H), 4.94 (s, 1H), 4.13 (dd, 1H), 3.93 (s, 3H), 3.85 (t, 1H), 3.41-3.48 (m, 1H), 2.92 (s, 3H). LCMS: m/z 429.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.58 (s, 1H), 8.17 (d, 1H), 7.40-7.47 (m, 2H), 6.96-7.03 (m, 2H), 6.89 (d, 1H), 6.80 (dd, 1H), 6.61 (t, 1H), 4.93 (s, 1H), 4.12 (dd, 1H), 3.01 (s, 3H), 3.85 (t, 1H), 3.45 (t, 1H), 2.91 (s, 3H). LCMS: m/z 392.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.16 (d, 1H), 7.99 (s, 1H), 7.49-7.58 (m, 2H), 6.94-7.03 (m, 2H), 6.88 (d, 1H), 6.77 (dd, 1H), 4.34 (dd, 1H), 3.91 (s, 3H), 3.06 (dd, 1H), 3.04 (s, 3H), 2.98 (s, 3H), 2.80 (dd, 1H). LCMS: m/z 452.6 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.06 (s, 1H), 8.14 (d, 1H), 7.47-7.58 (m, 2H), 6.93-7.04 (m, 2H), 6.88 (d, 1H), 6.78 (dd, 1H), 4.94 (dd, 1H), 3.92 (s, 3H), 3.87-3.98 (m, 1H), 3.56 (t, 1H), 2.91 (s, 3H), 2.59 (s, 3H). LCMS: m/z 452.5 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.07 (s, 1H), 8.24 (d, 1H), 8.14-8.18 (m, 1H), 7.65 (dd, 1H), 6.88-6.95 (m, 2H), 4.95 (dd, 1H), 3.93 (s, 3H), 3.90- 3.95 (m, 1H), 3.56 (t, 1H), 2.91 (s, 3H), 2.58 (s, 3H). LCMS: m/z 471.4 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.40- 8.43 (m, 1H), 8.26 (d, 1H), 7.92 (s, 1H), 7.88 (dd, 1H), 7.00 (d, 1H), 6.92 (d, 1H), 6.88 (dd, 1H), 5.89 (s, 1H), 3.92 (s, 3H), 3.70 (dd, 1H), 3.64 (t, 1H), 3.35-3.42 (m, 1H), 2.75 (dd, 1H), 2.60 (dd, 1H). LCMS: m/z 396.7 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.62 (s, 1H), 8.24-8.29 (m, 2H), 7.97 (d, 1H), 6.95 (d, 1H), 6.92 (dd, 1H), 5.09 (s, 1H), 4.13 (dd, 1H), 3.93 (s, 3H), 3.85 (t, 1H), 3.44 (dd, 1H), 2.92 (s, 3H). LCMS: m/z 445.5 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.67 (s, 1H), 8.40-8.44 (m, 1H), 8.25 (d, 1H), 7.88 (dd, 1H), 7.02 (d, 1H), 6.93 (d, 1H), 6.90 (dd, 1H), 3.96 (dd, 1H), 3.92 (s, 3H), 3.76 (t, 1H), 3.30 (dd, 1H), 2.91 (s, 3H), 2.85 (s, 3H). LCMS: m/z 425.8 [M + H]+
1H NMR (600 MHz, d6-DMSO) δ: 9.45 (s, 1H), 7.92 (d, 1H), 7.67-7.73 (m, 2H), 7.12 (d, 1H), 7.05-7.09 (m, 2H), 6.87 (dd, 1H), 4.69 (dd, 1H), 4.03-4.10 (m, 2H), 3.87 (s, 3H), 3.41-3.52 (m, 2H), 3.30 (s, 3H), 1.97-2.07 (m, 1H), 1.83- 1.97 (m, 3H). LCMS: m/z 453.8 [M + H]+
1H NMR (600 MHz, d6-DMSO) δ: 9.47 (s, 1H), 7.85 (d, 1H), 7.37 (t, 1H), 7.14 (ddd, 1H), 7.12 (d, 1H), 6.97 (t, 1H), 6.91 (ddd, 1H), 6.87 (dd, 1H), 6.46 (s, 1H), 4.38 (dd, 1H), 3.87 (s, 3H), 3.53 (t, 1H), 3.17 (ddd, 1H), 2.62 (s, 3H). LCMS: m/z 376.2 [M + H]+
1H NMR (600 MHz, d6-DMSO) δ: 9.52 (s, 1H), 7.87 (d, 1H), 7.69-7.72 (m, 2H), 7.12 (d, 1H), 7.05-7.09 (m, 2H), 6.90 (d, 1H), 3.88 (s, 3H), 3.50- 3.59 (m, 2H), 3.37-3.42 (m, 1H), 2.70 (s, 3H), 2.38-2.44 (m, 1H), 2.45- 2.5 (m, 1H). LCMS: m/z 409.5 [M + H]+
1H NMR (600 MHz, d6-DMSO) δ: 9.39 (s, 1H), 8.00 (d, 1H), 7.89-7.93 (m, 2H), 7.65-7.69 (m, 1H), 7.15 (d, 1H), 6.99 (d, 1H), 6.92 (dd, 1H), 4.39 (dd, 1H), 3.88 (s, 3H), 2.28-2.36 (m, 1H), 2.15-2.23 (m, 1H), 2.07-2.14 (m, 1H), 1.92-1.99 (m, 1H). LCMS: m/z 429.1 [M + H]+
1H NMR (600 MHz, d6-DMSO) δ: 10.42 (s, 1H), 8.60-8.63 (m, 1H), 8.28 (dd, 1H), 7.68 (t, 1H), 7.45 (t, 1H), 7.32 (d, 1H), 7.12 (d, 1H), 6.49 (s, 1H), 4.18 (dd, 1H), 3.55 (td, 1H), 3.18-3.23 (m, 1H), 2.63 (s, 3H). LCMS: m/z 415.3 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.82 (s, 1H), 8.45 (s, 1H), 7.93 (dd, 1H), 7.55- 7.62 (m, 2H), 7.06 (d, 1H), 6.95 (s, 1H), 4.14 (dd, 1H), 2.90 (s, 3H), 2.35-2.62 (m, 3H), 2.11-2.23 (m, 1H). LCMS: m/z 414.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.57 (s, 1H), 8.15 (d, 1H), 7.28-7.37 (m, 2H), 6.92-7.02 (m, 2H), 6.87 (d, 1H), 6.78 (dd, 1H), 5.32 (d, 2H), 4.86 (s, 1H), 4.12 (dd, 1H), 3.90 (s, 3H), 3.84 (t, 1H), 3.45 (t, 1H), 2.92 (s, 3H). LCMS: m/z 372.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.20 (s, 1H), 8.15 (d, 1H), 7.50-7.58 (m, 2H), 6.96-7.03 (m, 2H), 6.90 (d, 1H), 6.81 (dd, 1H), 4.62 (d, 1H), 4.41-4.48 (m, 1H), 3.92 (s, 3H), 3.84 (s, 3H), 3.70 (d, 1H), 2.43-2.65 (m, 3H), 2.13-2.25 (m, 1H). LCMS: m/z 467.5 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.20 (d, 1H), 7.91 (s, 1H), 7.50-7.57 (m, 2H), 6.95-7.02 (m, 2H), 6.89 (d, 1H), 6.79 (dd, 1H), 6.09 (s, 1H), 3.92 (s, 3H), 3.60-3.75 (m, 2H), 3.33-3.44 (m, 1H), 2.75 (dd, 1H), 2.61 (dd, 1H). LCMS: m/z 395.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.57 (s, 1H), 8.13 (d, 1H), 7.21-7.29 (m, 2H), 6.82-6.94 (m, 3H), 6.76 (dd, 1H), 4.96 (s, 1H), 4.12 (dd, 1H), 3.90 (s, 3H), 3.85 (t, 1H), 3.41-3.48 (m, 1H), 2.92 (s, 3H). LCMS: m/z 376.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.20 (d, 1H), 7.92 (s, 1H), 7.48-7.59 (m, 2H), 6.94-7.05 (m, 2H), 6.89 (d, 1H), 6.79 (dd, 1H), 6.12 (s, 1H), 3.92 (s, 3H), 3.59-3.77 (m, 2H), 3.32- 3.45 (m, 1H), 2.75 (dd, 1H), 2.61 (dd, 1H). LCMS: m/z 395.2 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 9.51 (s, 1H), 8.27 (d, 1H), 8.13-8.19 (m, 1H), 7.64 (dd, 1H), 6.83-6.96 (m, 2H), 4.73-4.80 (m, 1H), 3.92 (s, 3H), 3.54-3.62 (m, 1H), 3.42-3.51 (m, 1H), 2.45-2.54 (m, 1H), 2.14 (s, 3H), 2.08-2.22 (m, 1H), 1.97-2.07 (m, 1H), 1.81- 1.93 (m, 1H). LCMS: m/z 442.6 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.68 (s, 1H), 8.27-8.33 (m, 1H), 8.14-8.19 (m, 1H), 7.67 (dd, 1H), 6.87-6.99 (m, 2H), 3.96 (dd, 1H), 3.92 (s, 3H), 3.76 (t, 1H), 3.30 (dd, 1H), 2.91 (s, 3H), 2.85 (s, 3H). LCMS: m/z 443.3 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.44 (s, 1H), 8.03 (s, 1H), 7.89 (dd, 1H), 7.57 (d, 1H), 7.02 (d, 1H), 6.62 (d, 1H), 6.01-6.08 (m, 2H), 3.96 (dd, 1H), 3.77 (t, 1H), 3.30 (dd, 1H), 2.90 (s, 3H), 2.84 (s, 3H). LCMS: m/z 439.4 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.38 (s, 1H), 8.27 (t, 1H), 8.22 (s, 1H), 7.95 (dd, 1H), 7.13 (d, 1H), 7.06 (t, 1H), 5.11 (s, 1H), 4.15 (dd, 1H), 3.87 (t, 1H), 3.46 (t, 1H), 2.91 (s, 3H). LCMS: m/z 417.4 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.93 (s, 1H), 8.45 (s, 1H), 7.94 (dd, 1H), 7.42-7.50 (m, 1H), 7.39 (s, 1H), 7.06 (d, 1H), 6.65-6.73 (m, 1H), 5.12 (s, 1H), 4.14 (dd, 1H), 3.83 (t, 1H), 3.42 (t, 1H), 2.86 (s, 3H). LCMS: m/z 399.4 [M + H]+
1H NMR (600 MHz, CDCl3) δ: 8.10 (d, 1H), 7.77 (s, 1H), 7.55-7.61 (m, 2H), 7.14 (dd, 1H), 7.00-7.06 (m, 2H), 6.80 (ddd, 1H), 4.14 (dd, 1H), 2.93 (s, 3H), 2.54-2.62 (m, 1H), 2.39-2.54 (m, 2H), 2.11-2.19 (m, 1H). LCMS: m/z 397.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.40-8.45 (m, 1H), 8.14 (s, 1H), 7.92 (d, 1H), 7.88 (dd, 1H), 7.01 (d, 1H), 6.77-6.83 (m, 1H), 4.61-4.72 (m, 2H), 3.95 (dd, 1H), 3.76 (t, 1H), 3.23-3.34 (m, 3H), 2.90 (s, 3H), 2.84 (s, 3H). LCMS: m/z 437.4 [M + H]+
1H NMR (400 MHz, CDCl3) δ: 8.27 (s, 1H), 8.09 (dd, 1H), 7.53-7.63 (m, 2H), 7.14 (t, 1H), 6.99-7.08 (m, 2H), 6.76- 6.86 (m, 1H), 5.08 (s, 1H), 4.15 (dd, 1H), 3.87 (t, 1H), 3.42-3.51 (m, 1H), 2.92 (s, 3H). LCMS: m/z 398.3 [M + H]+
To a cooled (0-5 C) mixture of 1-methyl-5-oxopyrrolidine-2-carboxylic acid (0.067 g, 0.468 mmol) in dry DCM (1.5 ml) was added 1-chloro-N,N,2-trimethyl-1-propenylamine (0.065 ml, 0.488 mmol) and the mixture was stirred at 0-5° C. for 1 h. Then 2-bromo-5-(3-(trifluoromethyl)phenoxy)aniline (0.18 g, 0.390 mmol) dissolved in dry DMF (0.5 ml) and DIPEA (0.34 ml, 1.951 mmol) were added and the mixture was stirred at RT overnight. DCM was evaporated and the mixture diluted with EtOAc. Organic phase was washed with water and brine, dried and evaporated. Crude product was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.019 g. 1H NMR (600 MHZ, d6-DMSO) δ: 9.88 (s, 1H), 7.72 (d, 1H), 7.65 (t, 1H), 7.51-7.55 (m, 1H), 7.42 (d, 1H), 7.36-7.39 (m, 1H), 7.34 (dd, 1H), 6.93 (dd, 1H), 4.31-4.38 (m, 1H), 2.70 (s, 3H), 2.17-2.35 (m, 3H), 1.94-2.02 (m, 1H). LCMS: m/z 457.1 [M+H]+.
The compound was prepared according to the procedure of the preceding Example starting from 1-methyl-5-oxopyrrolidine-2-carboxylic acid (0.051 g, 0.359 mmol), DCM (1.5 ml), 1-chloro-N,N,2-trimethyl-1-propenylamine (0.057 ml, 0.431 mmol), 2-amino-4-(4-(trifluoromethyl)phenoxy)benzonitrile (0.10 g, 0.359 mmol) and DMF (0.75 ml). Yield: 0.022 g. 1H NMR (600 MHz, d6-DMSO) δ: 10.5 (s, 1H), 7.90 (d, 1H), 7.81-7.86 (m, 2H), 7-31-7.37 (m, 2H), 7.30 (d, 1H), 7.08 (dd, 1H), 4.30 (dd, 1H), 2.70 (s, 3H), 2.19-2.36 (m, 3H), 1.94-2.01 (m, 1H). LCMS: m/z 404.4 [M+H]+.
The compound was prepared using the procedure of Intermediate 306 staring from N-(2-fluoro-5-hydroxyphenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.071 g, 0.28 mmol), 2-chloro-5-(trifluoromethyl)pyridine (0.051 g, 0.28 mmol) and K2CO3 (0.058 g, 0.42 mmol) in dry DMF (1.0 ml). Crude was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.078 g. 1H NMR (600 MHz, CDCl3) δ: 8.40-8.43 (m, 1H), 8.21 (dd, 1H), 7.92 (dd, 1H), 7.79 (s, 1H), 7.18 (dd, 1H), 7.05 (d, 1H), 6.91 (dq, 1H), 4.15 8dd, 1H), 2.93 (s, 3H), 2.54-2.62 (m, 1H), 2.39-2.53 (m, 2H), 2.11-2.18 (m, 1H). LCMS: m/z 398.6 [M+H]+.
The compound was prepared using the procedure of Intermediate 339 staring from N-(2-fluoro-5-hydroxyphenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.071 g, 0.28 mmol), 2-chloro-5-(trifluoromethyl)pyridine (0.051 g, 0.28 mmol) and K2CO3 (0.058 g, 0.42 mmol) in dry DMF (1.0 ml). Crude was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.078 g. 1H NMR (600 MHz, CDCl3): δ 8.40-8.43 (m, 1H), 8.21 (dd, 1H), 7.92 (dd, 1H), 7.79 (s, 1H), 7.18 (dd, 1H), 7.05 (d, 1H), 6.91 (dq, 1H), 4.15 8dd, 1H), 2.93 (s, 3H), 2.54-2.62 (m, 1H), 2.39-2.53 (m, 2H), 2.11-2.18 (m, 1H). LCMS: m/z 398.6 [M+H]+.
To a mixture of palladium (10 wt-% on carbon, 0.045 g, 0.042 mmol) in methanol (15 ml) was added benzyl (2S,4R)-4-hydroxy-2-((2-methoxy-5-(4-(trifluoro-methyl)phenoxy)phenyl)carbamoyl)pyrrolidine-1-carboxylate (0.111 g, 0.209 mmol) dissolved in methanol (2.0 ml). The mixture was stirred vigorously while ammonium formate (0.132 mg, 2.09 mmol) was added. Stirring was continued at 50° C. until reaction was completed. Cooled mixture was filtered through a short plug of Celite. Celite was washed with methanol. Filtrate was evaporated and re-dissolved in EtOAc. Organic phase was washed with water and brine, dried and evaporated. Crude product was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.041 g. 1H NMR (600 MHz, d6-DMSO) δ:10.3 (s, 1H), 8.13 (d, 1H), 7.68-7.73 (m, 2H), 7.13 (d, 1H), 7.05-7.10 (m, 2H), 6.85 (dd, 1H), 4.71 (d, 1H), 4.16-4.20 (m, 1H), 3.89 (s, 3H), 3.87-3.93 (m, 1H), 3.48 (bs, 1H), 2.88 (d, 1H), 2.74 (d, 1H), 1.99-2.06 (m, 1H), 1.72-1.79 (m, 1H). LCMS: m/z 397.6 [M+H]+.
To a cooled (0-5° C.) solution of (S)—N-(2-methoxy-5-(4-(trifluoromethyl)-phenoxy)phenyl)-5-oxopyrrolidine-2-carboxamide (0.086 g, 0.225 mmol) in dry DCM (2.0 ml) was added acetyl chloride (0.018 ml, 0.248 mmol) dissolved in dry DCM (0.25 ml) and triethylamine (0.039 ml, 0.281 mmol) and the mixture was stirred overnight at RT. More acetyl chloride (0.018 ml, 0.248 mmol) and triethylamine (0.039 ml, 0.281 mmol) were added and stirring continued until the reaction was completed. The mixture was diluted with DCM and washed with water, saturated NaHCO3-solution and brine, dried and evaporated. Crude product was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.072 g. 1H NMR (400 MHz, CDCl3) δ: 9.44 (s, 1H), 8.18 (s, 1H), 7.43-7.60 (m, 2H), 6.91-7.07 (m, 2H), 6.86 (d, 1H), 6.74 (d, 1H), 4.75 (d, 1H), 3.91 (s, 3H), 3.59 (t, 1H), 3.47 (dd, 1H), 2.41-2.55 (m, 1H), 2.15 (s, 3H), 1.81-2.22. (m, 3H). LCMS: m/z 423.6 [M+H]+.
To a solution of Compound 48 (100 mg, 245 μmol) in DCM (5 ml) was added tetrabutyl ammonium iodide (90 mg, 245 μmol) at RT. The solution was cooled to −50° C. Then BCl3 1 M in heptane (1.469 ml, 1469 μmol) was added dropwise. The mixture was stirred for 10 min at −78° C. and then 1 h 20 min at RT. The mixture was diluted with DCM (10 ml) and poured into ice cold 1 N HCl (5 ml). Phases were separated. The aqueous phase was extracted twice with DCM. The combined organic phases were concentrated under reduced pressure. The crude product was purified by column chromatography to afford the title compound (0.055 g). 1H NMR (400 MHz, DMSO) δ: 10.06 (br s 1H), 9.57 (s, 1H), 7.79 (d, 1H), 7.69 (d, 2H), 7.05 (d, 2H), 6.94 (d, 1H), 6.80-6.75 (m, 1H), 4.50-4.42 (m, 1H), 2.65 (s, 3H), 2.31-2.12 (m, 3H), 1.95-1.84 (m, 1H). LCMS: m/z 395.4 [M+H]+
The following compound was prepared according to the procedure described for Compound 372. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
1H NMR (400 MHz, DMSO-d6) δ: 2.64 (3 H, s), 3.14-3.20 (1 H, m), 3.55 (1 H, t), 4.33-4.40 (1 H, m), 6.49 (1 H, br s), 6.78-6.83 (1 H, m), 6.93 (1 H, d), 7.14- 7.18 (1 H, m), 7.83 (1 H, d), 8.17-8.21 (1 H, m), 8.53-8.56 (1 H, m), 9.39 (1 H, br s), 10.14 (1 H, br s). LCMS: m/z 397.5 [M + H]+
tert-Butyl 3-((2-methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)carbamoyl)-4-methyl-5-oxopiperazine-1-carboxylate (30.6 mg, 58.5 μmol) was dissolved in HCl (dioxane solution) (2.13 g, 1.43 mL, 10 w-%, 5.85 mmol) and stirred at RT overnight. The mixture was purified by HPLC (Method D) to afford 12.9 mg of the title compound (12.9 mg, 30.5 μmol, 52.1%, 100% purity). 1H NMR (400 MHz, DMSO-d6) δ: 9.93 (s, 1H), 7.92 (d, 1H), 7.71 (d, 2H), 7.10 (dd, 3H), 6.91 (dd, 1H), 4.20 (s, 1H), 3.88 (d, 3H), 3.26 (s, 2H), 3.13 (s, 2H), 2.77 (s, 3H). LCMS: m/z 424.2 [M+H]+.
The following compounds were prepared according to the procedure described for Compound 374. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
Tert-butyl 4-methyl-3-oxo-5-((5-(4-(trifluoromethyl)phenoxy)-2,3-dihydro-benzofuran-7-yl)carbamoyl)piperazine-1-carboxylate (0.0416 g, 1 eq., 77.7 μmol) was dissolved in methanol (3 mL). TMS-Cl (42.2 mg, 49.3 μL, 5 eq., 388 μmol) was added dropwise. The mixture was stirred at 25° C. for 16 h and then concentrated under reduced pressure. The obtained mixture was subjected to HPLC (purification method D) to give the title compound (0.01 g, 0.02 mmol, 30%, 95% purity). 1H NMR (400 MHz, DMSO-d6) δ: 7.70 (d, 2H), 7.60 (s, 1H), 7.07 (d, 2H), 6.86 (s, 1H), 4.65 (t, 2H), 4.20 (t, 1H), 3.29-3.20 (m, 4H), 3.18-3.02 (m, 2H), 2.74 (s, 3H). LCMS: m/z 436.2 [M+H]+.
TFA (335 mg, 226 μL, 50 eq., 2.94 mmol) was added to (R)—N-(2-methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)-1-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-oxopyrrolidine-2-carboxamide (0.0341 g, 1 eq., 58.7 μmol) followed by refluxing the mixture for 16 h. Then the solvent was evaporated and the residue was purified by HPLC (Method G) to give the title compound (0.0057 g, 12 μmol, 21%, 100% purity). 1H NMR (400 MHz, Acetonitrile-d3) δ: 8.62 (s, 1H), 8.01 (d, 1H), 7.79 (s, 2H), 7.66 (d, 2H), 7.07 (dd, 3H), 6.88 (dd, 1H), 4.75 (dd, 1H), 3.92 (s, 3H), 2.66-2.36 (m, 4H), 2.23-2.13 (m, 2H). LCMS: m/z 459.1 [M−H]−.
The following compounds were prepared according to the procedure described for Compound 377. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
To a solution of 1-(2-cyanoethyl)-N-(2-methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)-5-oxopyrrolidine-2-carboxamide (158 mg, 1 eq., 353 μmol) in DMSO (2 mL) potassium carbonate (97.6 mg, 2 eq., 706 μmol) followed by hydrogen peroxide (343 mg, 309 μL, 35 w-%, 10 eq., 3.53 mmol) was added. The mixture was stirred at 40° C. for 36 h. Water (20 mL) was added to the residue and the resulted mixture was extracted with ethyl acetate (2×20 mL). Organic layers were combined, washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by reverse phase HPLC (purification method B) to afford the title compound (13.4 mg, 28.8 μmol, 8.15%, 100% purity) 1H NMR (400 MHz, DMSO-d6) δ: 9.64 (s, 1H), 7.89 (s, 1H), 7.70 (d, 2H), 7.36 (s, 1H), 7.19-7.05 (m, 3H), 6.92 (d, 1H), 6.82 (s, 1H), 4.63-4.55 (m, 1H), 3.88 (s, 3H), 3.64-3.51 (m, 1H), 3.20-2.96 (m, 2H), 2.31-2.12 (m, 4H), 1.96-1.85 (m, 1H). LCMS: m/z 466.2 [M+H]+.
(2S,4S)-4-((tert-Butyldimethylsilyl)oxy)-N-(2-methoxy-5-(4-(trifluoromethyl)-phenoxy)phenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.185 g, 1 eq., 343 μmol) was dissolved in THF (2 mL). Then TBAF (89.8 mg, 343 μL, 1 molar, 1 eq., 343 μmol) was added to the mixture dropwise at 0° C. The resulting mixture was stirred for 20 min and slowly heated to 20° C., stirred at this temperature for 10 h and purified by HPLC (purification method A) to give the title compound (0.0374 g, 88.1 μmol, 25.7%, 100% purity). 1H NMR (400 MHz, DMSO-d6) δ: 9.68 (s, 1H), 7.87 (s, 1H), 7.71 (d, 2H), 7.14 (d, 1H), 7.08 (d, 2H), 6.96-6.88 (m, 1H), 4.31 (t, 1H), 4.12 (t, 1H), 3.88 (s, 3H), 2.67 (s, 3H), 2.65-2.57 (m, 1H), 1.74-1.57 (m, 1H). LCMS: m/z 425.0 [M+H]+.
A mixture of N-(2-methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)tetrahydro-2H-thiopyran-4-carboxamide 1-oxide (250 mg, 1 eq., 585 μmol), phenyl-λ3-iodanediyl diacetate (565 mg, 3 eq., 1.75 mmol) and carbamic acid, ammonia salt (183 mg, 4 eq., 2.34 mmol) in methanol (12 mL) was stirred at 22° C. for 12 h. The mixture was concentrated to provide a mixture of a light yellow sludge and an immiscible colorless liquid. The mixture was washed twice with hexane (2×10 mL) by decantation and dried under vacuum. The residue was triturated and stirred in ethyl acetate, filtered, and the collected solid was washed with additional ethyl acetate. The filtrate was concentrated to provide a mixture of cis and trans isomers and purified by HPLC (purification method A) to give the title compound (30.5 mg, 65 μmol, 11%, 95% purity). 1H NMR (400 MHz, DMSO-d6) δ: 9.34 (d, 1H), 7.87 (t, 1H), 7.70 (d, 2H), 7.09 (dd, 3H), 6.88 (dd, 1H), 3.87 (s, 3H), 3.70 (s, 0H), 3.48 (s, 1H), 3.16-2.79 (m, 4H), 2.16-1.92 (m, 4H). LCMS: m/z 443.1 [M+H]+.
N-(5-(2-Chloro-4-(trifluoromethyl)phenoxy)-4-fluoro-2-methoxyphenyl)-3-methyl-2-oxoimidazolidine-4-carboxamide (0.032 g, 1 eq., 69 μmol) was dissolved in methanol (5 mL). Formic acid, ammonia salt (26 mg, 6 eq., 0.42 mmol) and palladium (7.4 mg, 10 w-%, 0.1 eq., 6.9 μmol) were added. The resulting mixture was stirred at 60° C. for 12 h, cooled to RT and filtered. The filtrate was concentrated under reduced pressure. The residue was dissolved in DMSO (2 mL) and to the obtained solution metal scavenger (SiliaMetS Dimercaptotriazine, 50 mg) was added. The mixture was stirred at RT for 3 h and filtered. The clear filtrate was purified by HPLC (purification method B) to give the title compound (0.0038 g, 8.4 μmol, 12%, 95% purity). 1H NMR (400 MHz, DMSO-d6) δ: 9.55 (s, 1H), 7.95 (d, 1H), 7.72 (d, 2H), 7.29 (d, 1H), 7.10 (d, 2H), 6.44 (s, 1H), 4.49-4.26 (m, 1H), 3.89 (s, 3H), 3.52 (t, 1H), 3.16 (t, 1H), 2.61 (s, 3H). LCMS: m/z 428.0 [M+H]+
To a solution of 1-methyl-6-oxo-N-(5-(4-(trifluoromethyl)phenoxy)-2,3-di-hydrobenzofuran-7-yl)piperazine-2-carboxamide (0.022 g, 1 eq., 51 μmol) in 1,4-dioxane (2 mL) was added NaCNBH4 (6.4 mg, 2 eq., 0.10 mmol) and water solution of formaldehyde (8.2 mg, 7.5 μL, 37 w-%, 2 eq., 0.10 mmol). Thereafter HOAc (0.01 mL) was added and the mixture was stirred at 25° C. for 12 h and evaporated. The residue was dissolved in DMSO (2 mL) and the metal scavenger (SiliaMetS Dimercaptotriazine, 10 mg) was added. The obtained mixture was stirred at RT for 3 h, filtered and the clear solution was purified by HPLC (purification method A) to afford the title compound (0.0052 g, 11 μmol, 22%, 95% purity). 1H NMR (500 MHz, DMSO-d6) δ: 9.97 (s, 1H), 7.68 (d, 2H), 7.57 (s, 1H), 7.05 (d, 2H), 6.84 (s, 1H), 4.63 (t, 2H), 4.20 (t, 1H), 3.23 (t, 2H), 3.12 (d, 1H), 2.93 (dd, 1H), 2.82-2.64 (m, 5H), 2.17 (s, 3H). LCMS: m/z 450.2 [M+H]+
N-(5-(2-Fluoro-4-nitrophenoxy)-2-methoxyphenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.080 g, 1 eq., 0.20 mmol) was dissolved in MeOH and dihydroxy-palladium (28 mg, 10 w-%, 0.1 eq., 20 μmol) was added. The resulting mixture was stirred under hydrogen atmosphere for 16 h, filtered and concentrated to give the title compound (0.065 g, 0.16 mmol, 79%, 90% purity). LCMS: m/z 393.0 [M+H]+
To a solution of N-(5-(4-amino-2-fluorophenoxy)-2-methoxyphenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.056 g, 1 eq., 0.15 mmol) in hydrochloric acid, 22% (0.5 mL) solution of sodium nitrite (12 mg, 1.2 eq., 0.18 mmol) in water (0.1 mL) was added at 0° C. The resulting mixture was stirred at the same temperature for 15 min, then the mixture was poured into solution of copper(I) chloride (21 mg, 1.4 eq., 0.21 mmol) in 37% hydrochloric acid (2 mL) at 0° C. The resulting mixture was stirred at 22° C. for 10 h. The mixture was concentrated under reduced pressure and purified by HPLC (purification method A) to give the title compound (0.0181 g, 46.1 μmol, 31%, 100% purity). 1H NMR (400 MHz, DMSO-d6) δ: 9.61 (s, 1H), 7.83 (d, 1H), 7.69-7.53 (m, 1H), 7.26 (d, 1H), 7.06 (t, 2H), 6.88-6.70 (m, 1H), 4.55-4.39 (m, 1H), 3.85 (s, 3H), 2.64 (s, 3H), 2.41-2.11 (m, 3H), 1.95-1.74 (m, 1H). LCMS: m/z 393.0 [M+H]+.
4-Acetylphenylboronic acid (0.33 g, 1.99 mmol), 4-methoxy-3-nitrophenol (0.28 g, 1.66 mmol), Cu(OAc)2 (0.451 mg, 2.48 mmol) and freshly activated powdered 4 Å molecular sieves were added to dry DCM (20 mL). Et3N (1.15 mL, 8.28 mmol) was then added to the mixture. The mixture was stirred under air atmosphere. Reaction progress was monitored by LCMS. After 24 h, the resulting slurry was filtered through celite and concentrated. The crude product was purified by flash column chromatography (heptane:EtOAc) to yield 0.3 g of the title compound. LCMS: m/z 288.21 [M+H]+.
A mixture of 1-(4-(4-methoxy-3-nitrophenoxy)phenyl)ethan-1-one (300 mg, 1.04 mmol), zinc (0.68 g, 10 eq., 10.44 mmol), ammonium chloride (0.56 g, 10 eq. 10.44 mmol) in THF (5 ml), MeOH (3 ml) and water (3 ml) was stirred at RT for 4 h. The mixture was filtered through celite. The filtrate was washed with water (2×30 mL), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography to afford (0.19 g) of the title compound. LCMS: m/z 258.65[M+H]+.
To a solution of 1-methyl-5-oxopyrrolidine-2-carboxylic acid (22.25 mg, 0.15 mmol), 1-(4-(3-amino-4-methoxyphenoxy)phenyl)ethan-1-one (40 mg, 0.16 mmol) and TEA (0.11, 0.78 mmol) in dry DMF (2 ml) at 0° C., was added 1-propanephosphonic acid cyclic anhydride (0.73 ml, 1.24 mmol). The mixture was stirred at RT overnight. The reaction mixture was quenched with water (10 ml) then extracted with ethyl acetate (2×10 ml). The combined organic layers were washed with 2 M NaHCO3, then with water, dried over sodium sulfate, evaporated and then purified by reverse phase chromatography to yield (40.5 mg) of the title compound. 1H NMR (600 MHz, DMSO-d6): δ: 1.86-1.92 (m, 1H), 2.16-2.30 (m, 3H), 2.52-2.54 (m, 3H), 2.61-2.65 (m, 3H), 3.89 (s, 3H), 4.47 (dd, 1H), 6.91 (dd, 1H), 6.98-7.01 (m, 2H), 7.14 (d, 1H), 7.87 (d, 1H), 7.94-8.02 (m, 2H), 9.65 (s, 1H). LCMS: m/z 383.28 [M+H]+.
A mixture of 2-methoxy-5-nitro benzaldehyde (0.5 g, 2.8 mmol) and toluene-sulfon hydrazide (0.51 g, 2.8 mmol) in 1,4-dioxane (5 ml) was heated at 60° C. for 90 min. To the crude (E)-N′-(2-methoxy-5-nitrobenzylidene)-4-methylbenzenesulfono-hydrazide was added K2CO3 (0.53 g, 3.86 mmol) and 4-(trifluoromethyl)phenylboronic acid (0.49 g, 2.6 mmol). The mixture was heated under nitrogen atmosphere at 110° C. for 4 h. After cooling at RT the mixture was quenched with 2 M NaHCO3 (5 ml). The mixture was extracted with ethyl acetate (2×10 ml). The combined organic layers were washed with water, dried, evaporated and then purified by flash chromatography to yield (0.35 g) of the title compound. LCMS: m/z 312.2 [M+H]+.
A mixture of 1-methoxy-4-nitro-2-(4-(trifluoromethyl)benzyl)benzene (100 mg, 0.32 mmol), zinc (0.21 g, 10 eq., 3.21 mmol) and ammonium chloride (0.17 g, 10 eq. 3.21 mmol) in THF (10 ml), MeOH (3 ml) and water (3 ml) was stirred at RT for 4 h. The mixture was filtered through celite. The filtrate was washed with water (2×30 mL), dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography to afford (0.12 g) of the title compound. LCMS: m/z 282.05 [M+H]+.
To a solution of 1-methyl-5-oxopyrrolidine-2-carboxylic acid (45.8 mg, 0.32 mmol), 4-methoxy-3-(4-(trifluoromethyl)benzyl)aniline (90 mg, 0.32 mmol) and TEA (0.22, 1.60 mmol) in dry DMF (2 ml) at 0° C. was added 1-propanephosphonic acid cyclic anhydride (1.51 ml, 2.56 mmol). The mixture was stirred at RT overnight. The reaction mixture was quenched with water (10 ml) then extracted with ethyl acetate (2×10 ml). The combined organic layers were washed with 2 M NaHCO3, then with water, dried over sodium sulfate, evaporated and then purified by reverse phase chromatography to yield (5 mg) of the title compound. 1H NMR (400 MHz, Chloroform-d) δ: 1.75-2.02 (m, 1H), 2.06-2.22 (m, 1H), 2.31-2.59 (m, 3H), 2.81-2.91 (m, 3H), 3.79-3.93 (m, 3H), 3.96-4.10 (m, 3H), 6.85 (d, 1H), 7.25-7.33 (m, 4H), 7.44-7.57 (m, 3H), 7.84 (br s, 1H). LCMS: m/z 282.05 [M+H]+.
TMA (2 M in Chlorobenzene, 397 μL, 0.794 mmol) was added to a mixture of 2-methoxy-5-(4-(trifluoromethyl)phenoxy)aniline (0.075 g, 0.265 mmol) and ethyl-2-oxo-2,3-dihydrooxazole-4-carboxylate (0.064 g, 0.397 mmol) in toluene (2 ml) followed by heating the mixture at 90° C. for 3 h. The reaction mixture was quenched with ice cold water. The aqueous layer was extracted with EtOAc (2×5 ml). The combined organic layers were evaporated and then purified by reverse phase chromatography to yield 0.029 g of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 3.87 (3H, s), 7.00 (1H, m), 7.11 (2H, d), 7.17 (1H, d), 7.59 (1H, d), 7.72 (2H, d), 7.98 (1H, s), 9.46 (1H, s), 11.44 (1H, br s). LCMS: m/z 395.2 [M+H]+
To a solution of 1-methyl-5-oxopyrrolidine-2-carboxylic acid (15 mg, 0.10 mmol), 3-(3,4-difluorophenoxy)-6-methoxy-2-methylaniline (24 mg, 0.09 mmol), T3P (50% in EtOAc, 80 μl, 0.14 mmol) and DCM (2 ml) was added DIPEA (47 μl, 0.27 mmol). After refluxing for 3 h, additional starting material and reagents were added (1-methyl-5-oxopyrrolidine-2-carboxylic acid 1.15 eq., T3P 1.5 eq., DIPEA 3.0 eq.) followed by stirring in a closed vessel at 80° C. for 7 h. The reaction mixture was quenched with 2N NaOH (2 ml). The organic layer was separated and the aqueous layer was extracted with EtOAc (1×4 ml). The combined organic layers were evaporated and then purified by reverse phase chromatography to yield 0.016 g of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 1.94 (3H, s), 1.94-2.03 (1H, m), 2.19-2.37 (3H, m), 2.71 (3H, s), 3.79 (3H, s), 4.26-4.33 (1H, m), 6.61 (1H, m), 6.90-7.02 (3H, m), 7.36-7.45 (1H, m), 9.66 (1H, s). LCMS: m/z 391.1 [M+H]+
The following compounds were prepared according to the procedure described for Compound 389. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
BCl3 (1M in heptane, 798 μL, 0.798 mmol) was added dropwise to a cooled solution of N-(2-methoxy-5-(3-methoxy-4-(trifluoromethyl)phenoxy)phenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.100 g, 0.228 mmol) in DCM (9 ml) at −50° C. followed by stirring at RT for 50 min. The reaction mixture was quenched with 1 N HCl (5 ml). The organic layer was separated and evaporated. The residue was purified by reverse phase chromatography to yield 0.066 g of the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 1.85-1.95 (1H, m), 2.13-2.35 (3H, m), 2.65 (3H, s), 3.84 (3H, s), 4.43-4.50 (1H, m), 6.42 (1H, m), 6.78 (1H, m), 6.86 (1H, d), 6.94 (1H, d), 7.53 (1H, d), 7.79 (1H, d), 9.57 (1H, s), 10.07 (1H, s). LCMS: m/z 425.2 [M+H]+
NaH (60% in oil, 0.028 g, 0.704 mmol) was added to a cooled solution of N-(5-(2-fluoro-4-(trifluoromethyl)phenoxy)-2-methoxyphenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.100 g, 0.235 mmol) in DMF (2 ml) at 0° C. followed by stirring for 15 min at RT. Then 2-(Methylsulfonyl)ethanol was added and the mixture was heated at 50° C. for 2.5 h. Additional NaH (60% in oil, 5 eq.) and 2-(Methylsulfonyl)ethanol were then added twice and heated at 80° C. for 5 h and at 100° C. for 5.5 h, respectively. The reaction mixture was quenched with 2 N HCl (2 ml) and extracted with EtOAc (3×3 ml). The organic layer was separated and evaporated. The residue was purified by reverse phase chromatography to yield 0.012 g of the title compound. 1H NMR (600 MHz, DMSO-d6) δ: 1.85-1.92 (1H, m), 2.16-2.31 (3H, m), 2.64 (3H, s), 3.85 (3H, s), 4.46 (1H, m), 6.76 (1H, m), 6.92 (1H, d), 7.07 (1H, d), 7.11 (1H, m), 7.20 (1H, d), 7.80 (1H, d), 9.58 (1H, s), 10.17 (1H, s). LCMS: m/z 425.2 [M+H]+
N-(2-Methoxy-5-(4-(trifluoromethyl)phenoxy)phenyl)pyrrolidine-3-carboxamide (74 mg, 1 Eq., 1.321 mmol) and Et3N (271 μL, 10 eq., 1.945 mmol) were dissolved in DCM (5 mL) under nitrogen. Acetyl chloride was added dropwise at 0° C. and the mixture was stirred and gradually raised to RT. After completion the reaction, the mixture was diluted with EtOAc (20 ml) and washed with brine (2×10 ml). The organic phase was dried over sodium sulfate, filtered and concentrated. The crude residue was purified further with reverse phase chromatography to obtain 36 mg of the title compound. 1H NMR (400 MHz, CDCl3 mixture of rotamers in ˜1.0:1.2 ratio) δ: 8.19 (m, 1H), 7.93 (br s, 0.45H), 7.88 (br s, 0.52H), 7.57-7.50 (m, 2.1H), 7.02-6.94 (m, 2.1H), 6.90 (m, 1.1H), 6.78 (m, 1H), 3.93 (s, 1.54H), 3.92 (s, 1.72H), 3.91-3.84 (m, 0.59H), 3.81-3.65 (m, 2.7H), 3.55-3.42 (m, 1.12H), 3.16 (m, 0.5H), 3.06 (quin, 0.58H) 2.45-2.34 (m, 0.67H), 2.31-2.16 (m, 1.8H), 2.08 (s, 1.44H), 2.07 (s, 1.63H). LCMS: m/z 423.2 [M+H]+
The following compounds were prepared according to the procedure described for Compound 412. The compound code, structure, starting materials, purification method and characterization data are indicated in the table.
In a Buchner flask benzyl (2-(2-((2-methoxy-5-(4-(trifluoromethyl)phenoxy)-phenyl)carbamoyl)-5-oxopyrrolidin-1-yl)-2-oxoethyl)carbamate (168 mg, 0.287 mmol, 1 eq.) was dissolved in EtOH (10 ml) and palladium (24.4 mg, 0.023 mmol, 0.08 eq.) and HCl (37%, 0.120 ml, 1.435 mmol, 5 eq.) was added. The flask was connected to a H2/N2/vacuum line and after replacement of air with nitrogen, the mixture was stirred under hydrogen for 2.5 h. The mixture was filtered through a pad of Celite® and washed with a 1:1 mixture of acetonitrile/H2O. The product was frozen at −78° C. and solvents removed on freeze dryer to obtain the title compound. 1H NMR (400 MHz, DMSO-d6) δ: 9.91 (s, 1H), 8.17 (br.s, 1H), 7.85 (d, 1H), 7.70 (d, 2H), 7.15 (d, 1H), 7.06 (d, 2H), 6.93 (dd, 1H), 5.15 (m, 1H), 4.20 (d, 1H), 4.17 (d, 1H), 3.91 (s, 3H), 2.71-2.30 (m, 3H), 2.04 (m, 1H). LCMS: m/z 452.598 [M+H]+
The compound was prepared according to the procedure described for Intermediate 364 starting from tert-butyl (S)-2-((2-methoxy-5-(4-(trifluoromethyl)-phenoxy)phenyl)carbamoyl)-5-oxopyrrolidine-1-carboxylate. The crude end product was treated with saturated Na2CO3 solution and then extracted with DCM. The organic phase was dried and evaporated to obtain the title compound. 1H NMR (400 MHz, CDCl3) δ: 10.2 (s, 1H), 8.27 (d, 1H), 7.48-7.56 (m, 2H), 6.96-7.03 (m, 2H), 6.87 (d, 1H), 6.74 (dd, 1H), 3.91 (s, 3H), 3.85-3.92 (m, 1H), 2.98-3.15 (m, 2H), 2.14-2.26 (m, 1H), 1.97-2.08 (m, 1H), 1.68-1.85 (m, 2H). LCMS: m/z 381.7 [M+H]+
The compound was prepared according to the procedure described for Intermediate 364 starting from tert-butyl (2S)-2-((5-((3-fluoro-5-(trifluoromethyl)-pyridin-2-yl)oxy)-2-methoxyphenyl)carbamoyl)-114-pyrrolidine-1-carboxylate. The crude end product was treated with saturated Na2CO3 solution and then extracted with DCM. The organic phase was dried and evaporated to obtain the title compound. 1H NMR (400 MHz, CDCl3) δ: 10.2 (s, 1H), 8.37 (d, 1H), 8.14-8.19 (m, 1H), 7.64 (dd, 1H), 6.91 (d, 1H), 6.86 (dd, 1H), 3.92 (s, 3H), 3.86 (dd, 1H), 2.96-3.14 (m, 2H), 2.13 (br, 1H), 2.12-2.24 (m, 1H), 1.96-2.07 (m, 1H), 1.67-1.84 (m, 2H). LCMS: m/z 400.6 [M+H]+
To a cooled (0-5° C.) solution of (S)—N-(2-methoxy-5-(4-(trifluoromethyl)-phenoxy)phenyl)-1-methyl-5-oxopyrrolidine-2-carboxamide (0.204 g, 0.50 mmol) in dry DMF (2.0 mmol) was added sodium hydride, 60 wt-% in oil (0.025 g, 0.625 mmol) followed by stirring the mixture at 0-5° C. for 15 min. Iodomethane (0.062 ml, 1.00 mmol) was added and stirring was continued at RT until reaction was completed. The mixture was diluted with water and extracted with EtOAc. Organic phase was washed with water and brine, dried and evaporated. Crude product was purified by reverse phase flash chromatography to afford the title compound. Yield: 0.152 g. 1H NMR (400 MHz, CDCl3), mixture of rotamers. Chemical shifts for the main rotamer: δ: 7.56-7.64 (m, 2H), 7.07-7.14 (m, 1H), 6.98-7.06 (m, 3H), 6.96 (dd, 1H), 3.93 (dd, 1H), 3.90 (s, 3H), 3.21 (s, 3H), 2.76 (s, 3H), 2.43-2.62 (m, 1H), 2.18-2.31 (m, 1H), 1.77-2.08 (m, 2H). LCMS: m/z 423.4 [M+H]+.
TEAD inhibition was assayed using Hippo Pathway TEAD Reporter—MCF-7 cell line (BPS Bioscience, Catalog #: 60618) which contains firefly luciferase gene under the control of TEAD responsive elements. In the cell line, YAP1 remains in the nucleus inducing constitutive expression of luciferase reporter. Amount of expressed luciferase was detected using ONE-Glo Luciferase Assay System (Promega) and measuring plates with Enspire Multimode Plate Reader (PerkinElmer).
Hippo Pathway TEAD Reporter—MCF-7 cells were plated on white/clear Poly-D-Lysine coated 384 plates (Corning #356660) at the density of 8500 cells/well. Next day test compounds (11 concentrations with 4 replicates) and DMSO control (0.1%) were added to the plate. After 24 h cells were lysed and luciferase activity was measured. The half maximal inhibitory concentration (IC50) of the test compounds on YAP-TEAD inhibition was determined.
The compounds of the invention were screened in the above mentioned assay and the IC50 values of the compounds are set forth in Table 1 below wherein “A” refers to a group of compounds having IC50 value of less than 50 nM, “B” refers to a group of compounds having IC50 value in range of 50 to 300 nM and “C” refers to a group of compounds having IC50 value in range of 301 nM to 2000 nM.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20217071 | Apr 2021 | FI | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/FI2022/050249 | 4/14/2022 | WO |
